STATE OF ILLINOIS
HOUSE JOURNAL
HOUSE OF REPRESENTATIVES
NINETY-FIRST GENERAL ASSEMBLY
111TH LEGISLATIVE DAY
FRIDAY, MARCH 24, 2000
12:30 O'CLOCK P.M.
NO. 111
[March 24, 2000] 2
HOUSE OF REPRESENTATIVES
Daily Journal Index
111th Legislative Day
Action Page(s)
Adjournment........................................ 56
Committee on Rules Referrals....................... 6
Correctional Budget & Impact Note Requested........ 6
Fiscal Notes Requested............................. 6
Home Rule Notes Requested.......................... 7
Housing Affordability Impact Note Requested........ 7
Judicial Note Requested............................ 7
Land Conveyance Appraisal Note Requested........... 7
Letter of Transmittal.............................. 5
Pension Impact Note Requested...................... 7
Quorum Roll Call................................... 5
Re-referred to the Committee on Rules.............. 6
State Mandate Notes Requested...................... 6
Temporary Committee Assignments.................... 5
Bill Number Legislative Action Page(s)
HB 0486 Senate Message - Passage w/ SA..................... 15
HB 2574 Senate Message - Passage w/ SA..................... 42
HB 3188 Senate Message - Passage w/ SA..................... 43
HB 4043 Senate Message - Passage w/ SA..................... 43
HB 4348 Senate Message - Passage w/ SA..................... 44
HR 0622 Committee Report................................... 8
HR 0637 Committee Report................................... 8
HR 0656 Adoption........................................... 55
HR 0657 Adoption........................................... 55
HR 0658 Adoption........................................... 55
HR 0659 Adoption........................................... 55
HR 0660 Adoption........................................... 55
HR 0663 Adoption........................................... 55
HR 0664 Adoption........................................... 55
HR 0664 Adoption........................................... 55
HR 0665 Adoption........................................... 55
HR 0665 Adoption........................................... 55
HR 0666 Adoption........................................... 55
HR 0667 Adoption........................................... 55
HR 0668 Adoption........................................... 55
HR 0670 Adoption........................................... 55
HR 0672 Adoption........................................... 55
HR 0673 Adoption........................................... 55
HR 0674 Adoption........................................... 55
HR 0675 Adoption........................................... 55
HR 0676 Adoption........................................... 55
HR 0692 Adoption........................................... 55
SB 0121 Committee Report................................... 9
SB 0334 Committee Report................................... 11
SB 0649 Second Reading - Amendment/s....................... 44
SB 0730 Committee Report................................... 9
SB 0810 Committee Report................................... 11
SB 1249 Committee Report................................... 11
SB 1268 Committee Report................................... 9
SB 1273 Committee Report................................... 9
SB 1277 Committee Report................................... 11
SB 1284 Second Reading - Amendment/s....................... 45
SB 1288 Committee Report................................... 8
SB 1291 Committee Report................................... 11
SB 1294 Committee Report................................... 10
3 [March 24, 2000]
Bill Number Legislative Action Page(s)
SB 1295 Committee Report................................... 8
SB 1296 Committee Report................................... 11
SB 1297 Second Reading..................................... 44
SB 1297 Second Reading..................................... 44
SB 1298 Committee Report................................... 12
SB 1303 Committee Report................................... 11
SB 1304 Committee Report................................... 11
SB 1307 Committee Report................................... 11
SB 1317 Committee Report................................... 11
SB 1319 Committee Report................................... 9
SB 1323 Committee Report................................... 11
SB 1326 Second Reading..................................... 44
SB 1330 Committee Report................................... 10
SB 1332 Committee Report................................... 9
SB 1338 Second Reading..................................... 44
SB 1339 Committee Report................................... 11
SB 1359 Second Reading..................................... 44
SB 1360 Committee Report................................... 9
SB 1361 Committee Report................................... 9
SB 1362 Committee Report................................... 9
SB 1363 Committee Report................................... 9
SB 1364 Committee Report................................... 9
SB 1365 Committee Report................................... 9
SB 1376 Committee Report................................... 10
SB 1377 Committee Report................................... 10
SB 1382 Committee Report................................... 9
SB 1389 Committee Report................................... 8
SB 1391 Committee Report................................... 8
SB 1397 Second Reading..................................... 44
SB 1398 Second Reading..................................... 44
SB 1404 Committee Report................................... 11
SB 1426 Committee Report................................... 9
SB 1434 Second Reading..................................... 44
SB 1444 Committee Report................................... 8
SB 1451 Committee Report................................... 13
SB 1474 Second Reading..................................... 44
SB 1477 Committee Report................................... 10
SB 1498 Second Reading..................................... 44
SB 1504 Committee Report................................... 10
SB 1513 Committee Report................................... 12
SB 1537 Committee Report................................... 8
SB 1540 Committee Report................................... 12
SB 1541 Committee Report................................... 8
SB 1550 Second Reading - Amendment/s....................... 50
SB 1588 Committee Report................................... 12
SB 1588 Committee Report................................... 12
SB 1589 Committee Report................................... 8
SB 1613 Second Reading..................................... 44
SB 1617 Second Reading..................................... 44
SB 1620 Committee Report................................... 9
SB 1626 Committee Report................................... 12
SB 1627 Committee Report................................... 11
SB 1630 Second Reading..................................... 44
SB 1638 Committee Report................................... 7
SB 1645 Committee Report................................... 11
SB 1648 Second Reading..................................... 44
SB 1650 Second Reading..................................... 44
SB 1651 Committee Report................................... 11
SB 1659 Committee Report................................... 12
SB 1674 Committee Report................................... 11
SB 1682 Second Reading - Amendment/s....................... 54
SB 1690 Second Reading - Amendment/s....................... 54
SB 1693 Committee Report................................... 11
SB 1695 Committee Report................................... 9
[March 24, 2000] 4
Bill Number Legislative Action Page(s)
SB 1701 Second Reading..................................... 44
SB 1707 Committee Report................................... 11
SB 1734 Committee Report................................... 11
SB 1780 Committee Report................................... 7
SB 1851 Committee Report................................... 12
SB 1852 Committee Report................................... 8
SB 1861 Second Reading..................................... 44
SB 1862 Committee Report................................... 8
SB 1871 Committee Report................................... 12
SB 1874 Committee Report................................... 11
SB 1881 Committee Report................................... 10
SB 1883 Committee Report................................... 11
SB 1899 Committee Report................................... 11
SB 1923 Committee Report................................... 8
SB 1929 Committee Report................................... 11
SB 2963 Action on Motion................................... 50
SJR 0065 Senate Message..................................... 55
5 [March 24, 2000]
The House met pursuant to adjournment.
The Speaker in the Chair.
Prayer by Reverend Billy Green with the Gospel Mission Tabernacle
in Golconda, Illinois.
Representative Hassert led the House in the Pledge of Allegiance.
By direction of the Speaker, a roll call was taken to ascertain the
attendance of Members, as follows:
113 present. (ROLL CALL 1)
By unanimous consent, Representatives Erwin, Giglio, Lindner,
Persico and Zickus were excused from attendance.
TEMPORARY COMMITTEE ASSIGNMENTS
The Speaker announced the following temporary committee
assignments:
Representative Hartke will replace Representative Mautino, and
Representative Hartke will replace Representative Granberg in the
Committee on Revenue, for today only.
Representative Flowers replaced Representative Currie in the
Committee on Revenue on March 16, 2000.
Representative Morrow will replace Representative Giglio in the
Committee on Transportation & Motor Vehicles, for today only.
Representative Flowers replaced Representative Currie in the
Committee on Prosecutorial Misconduct on March 14, 2000.
Representative Burke replaced Representative Hannig in the
Committee on Rules on March 16, 2000.
Representative Scott replaced Representative Osterman in the
Committee on Children and Youth on March 22, 2000.
Representative Steve Davis replaced Representative Lopez in the
Committee on Insurance on March 22, 2000.
Representative Stroger replaced Representative Giglio in the
Committee on Transportation & Motor Vehicles on March 22, 2000.
Representative McKeon replaced Representative Smith in the
Committee on Elementary & Secondary Education on March 23, 2000.
Representative Scott replaced Representative Stroger in the
Committee on Environment and Energy on March 23, 2000.
Representative Smith will replace Representative Scott,
Representative Schoenberg will replace Representative O'Brien, and
Representative Scott will replace Representative Smith, in the
Committee on Judiciary II - Criminal Law, for today only.
Representative Woolard will replace Representative Acevedo in the
Committee on Local Government, for today only.
LETTER OF TRANSMITTAL
GENERAL ASSEMBLY
STATE OF ILLINOIS
March 24, 2000
Anthony D. Rossi
Clerk of the House
HOUSE OF REPRESENTATIVES
402 Capitol Building
Springfield, IL 62706
Dear Mr. Clerk:
Please be advised that I have extended the Committee Deadline to March
30, 2000 for SENATE BILLS 1248, 1340, 1582, 1828, 1829 and 1888.
If you have questions, please contact my Chief of Staff, Tim Mapes.
[March 24, 2000] 6
With kindest personal regards, I remain
Sincerely yours,
s/MICHAEL J. MADIGAN
Speaker of the House
GENERAL ASSEMBLY
STATE OF ILLINOIS
March 24, 2000
Anthony D. Rossi
Clerk of the House
HOUSE OF REPRESENTATIVES
402 Capitol Building
Springfield, IL 62706
Dear Mr. Clerk:
Please be advised that I have extended the Committee Deadline to March
30, 2000 for SENATE BILL 1278.
If you have questions, please contact my Chief of Staff, Tim Mapes.
With kindest personal regards, I remain
Sincerely yours,
s/MICHAEL J. MADIGAN
Speaker of the House
RE-REFERRED TO THE COMMITTEE ON RULES
The following bills were re-referred to the Committee on Rules
pursuant to Rule 19(a): SENATE BILLS 174, 252, 777, 1276, 1293, 1331,
1393, 1409, 1571, 1653 and 1718.
COMMITTEE ON RULES
REFERRALS
Representative Barbara Flynn Currie, Chairperson of the Committee
on Rules, reported the following legislative measures and/or joint
action motions have been assigned as follows:
Committee on Appropriations-General Services & Government
Oversight: SENATE BILLS 1828 and 1829.
Committee on Elementary & Secondary Education: SENATE BILL 1888.
Committee on Executive: SENATE BILL 1340.
Committee on Local Government: SENATE BILL 1582.
Committee on Transportation & Motor Vehicles: SENATE BILL 1248.
REQUEST FOR FISCAL NOTES
Representative Black requested that Fiscal Notes be supplied for
SENATE BILLS 730, as amended, and 807, as amended.
REQUEST FOR STATE MANDATE NOTES
Representative Black requested that State Mandate Notes be supplied
for SENATE BILLS 730, as amended, and 807, as amended.
REQUEST FOR CORRECTIONAL BUDGET & IMPACT NOTE
7 [March 24, 2000]
Representative Black requested that a Correctional Budget & Impact
Note be supplied for SENATE BILL 730, as amended.
REQUEST FOR HOME RULE NOTES
Representative Black requested that a Home Rule Note be supplied
for HOUSE BILL 730, as amended.
REQUEST FOR HOUSING AFFORDABILITY IMPACT NOTE
Representative Black requested that a Housing Affordability Impact
Note be supplied for SENATE BILL 730, as amended.
REQUEST FOR JUDICIAL NOTE
Representative Black requested that a Judicial Note be supplied for
SENATE BILL 730, as amended.
REQUEST FOR LAND CONVEYANCE APPRAISAL NOTE
Representative Black requested that a Land Conveyance Appraisal
Note be supplied for SENATE BILL 730, as amended.
REQUEST FOR PENSION IMPACT NOTE
Representative Black requested that a Pension Impact Note be
supplied for SENATE BILL 730, as amended.
REPORTS FROM STANDING COMMITTEES
Representative Monique Davis, Chairperson, from the Committee on
Appropriations - Human Services to which the following were referred,
action taken earlier today, and reported the same back with the
following recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1780.
The committee roll call vote on SENATE BILL 1780 is as follows:
9, Yeas; 0, Nays; 0, Answering Present.
Y Davis, Monique, Chair Y Leitch
Y Bellock Y McKeon
Y Feigenholtz Y Mulligan, Spkpn
Y Hamos Y Osterman
A Hultgren Y Reitz
A Saviano
Representative Lyons, Chairperson, from the Committee on Child
Support Enforcement to which the following were referred, action taken
on March 23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1638.
The committee roll call vote on SENATE BILL 1638 is as follows:
8, Yeas; 0, Nays; 0, Answering Present.
Y Lyons, Joseph, Chair Y Giglio
Y Bellock Y Hamos
A Black A Lyons, Eileen, Spkpn
Y Brady Y McCarthy
Y Crotty A Mitchell, Jerry
[March 24, 2000] 8
A Curry, Julie A O'Brien, V-Chair
Y Schmitz
Representative Novak, Chairperson, from the Committee on
Environment & Energy to which the following were referred, action taken
on March 23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILL 1391.
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Standard Debate: SENATE BILL 1541.
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1288.
That the resolution be reported "be adopted" and be placed on the
House Calendar: HOUSE RESOLUTION 637.
The committee roll call vote on SENATE BILLS 1288, 1391 and HOUSE
RESOLUTION 637 is as follows:
15, Yeas; 0, Nays; 0, Answering Present.
Y Novak, Chair Y Hultgren
Y Beaubien Y Jones, Shirley
Y Bradley Y Lawfer
Y Davis, Steve, V-Chair A Moore, Andrea
Y Durkin Y Murphy
Y Hartke Y Parke
Y Hassert, Spkpn A Persico
Y Holbrook Y Reitz
Y Stroger (Scott)
The committee roll call vote on SENATE BILL 1541 is as follows:
9, Yeas; 3, Nays; 4, Answering Present.
Y Novak, Chair P Hultgren
Y Beaubien P Jones, Shirley
N Bradley Y Lawfer
Y Davis, Steve, V-Chair Y Moore, Andrea
Y Durkin P Murphy
N Hartke Y Parke
Y Hassert, Spkpn A Persico
N Holbrook Y Reitz
P Stroger (Scott)
Representative Erwin, Chairperson, from the Committee on Higher
Education to which the following were referred, action taken on March
23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1295, 1389, 1444, 1537,
1589 and 1862.
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILLS 1852 and 1923.
That the resolution be reported "be adopted" and be placed on the
House Calendar: HOUSE RESOLUTION 622.
The committee roll call vote on SENATE BILLS 1389, 1444, 1537,
1589, 1862, 1923 and HOUSE RESOLUTION 622 is as follows:
14, Yeas; 0, Nays; 0, Answering Present.
Y Erwin, Chair A Lopez
Y Bost Y Myers, Richard
Y Davis, Monique Y Righter
Y Giles Y Smith, Michael
Y Howard Y Winkel
Y Johnson, Tim Y Wirsing, Spkpn
Y Klingler Y Woolard
Y Younge
9 [March 24, 2000]
The committee roll call vote on SENATE BILL 1295 is as follows:
12, Yeas; 0, Nays; 0, Answering Present.
Y Erwin, Chair A Lopez
Y Bost Y Myers, Richard
Y Davis, Monique Y Righter
A Giles A Smith, Michael
Y Howard Y Winkel
Y Johnson, Tim Y Wirsing, Spkpn
Y Klingler Y Woolard
Y Younge
The committee roll call vote on SENATE BILL 1852 is as follows:
12, Yeas; 0, Nays; 2, Answering Present.
Y Erwin, Chair A Lopez
Y Bost Y Myers, Richard
Y Davis, Monique Y Righter
P Giles Y Smith, Michael
Y Howard Y Winkel
Y Johnson, Tim Y Wirsing, Spkpn
Y Klingler Y Woolard
P Younge
Representative Gash, Chairperson, from the Committee on Judiciary
II - Criminal Law to which the following were referred, action taken
earlier today, and reported the same back with the following
recommendations:
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Standard Debate: SENATE BILLS 121 and 730.
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILLS 1268 and 1332.
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1273, 1319, 1360, 1361,
1362, 1363, 1364, 1365, 1382, 1426, 1620 and 1695.
The committee roll call vote on SENATE BILLS 1273, 1319, 1382,
1620, and 1695 is as follows:
13, Yeas; 0, Nays; 0, Answering Present.
Y Gash, Chair Y Lindner (Righter)
Y Bradley Y Lyons, Eileen
Y Delgado Y O'Brien
Y Durkin Y Scully
Y Johnson, Tom Y Smith, Michael, V-Chair (Scott)
Y Jones, Lou Y Turner, John
Y Winkel, Spkpn
The committee roll call vote on SENATE BILLS 1268, 1332, 1360,
1362, 1363, 1364, 1365, and 1426 is as follows:
13, Yeas; 0, Nays; 0, Answering Present.
Y Gash, Chair Y Lindner (Righter)
Y Bradley Y Lyons, Eileen (Mathias)
Y Delgado Y O'Brien
Y Durkin Y Scully
Y Johnson, Tom Y Smith, Michael, V-Chair (Scott)
Y Jones, Lou Y Turner, John
Y Winkel, Spkpn
The committee roll call vote on SENATE BILL 121 is as follows:
7, Yeas; 5, Nays; 1, Answering Present.
Y Gash, Chair N Lindner (Righter)
Y Bradley P Lyons, Eileen (Mathias)
Y Delgado Y O'Brien
N Durkin Y Scully
[March 24, 2000] 10
N Johnson, Tom Y Smith, Michael, V-Chair (Scott)
Y Jones, Lou N Turner, John
N Winkel, Spkpn
The committee roll call vote on SENATE BILL 730 is as follows:
7, Yeas; 6, Nays; 0, Answering Present.
Y Gash, Chair N Lindner (Righter)
Y Bradley N Lyons, Eileen
Y Delgado Y O'Brien (Schoenberg)
N Durkin Y Scully
N Johnson, Tom Y Smith, Michael, V-Chair (Scott)
Y Jones, Lou N Turner, John
N Winkel, Spkpn
Representative Stroger, Chairperson, from the Committee on Labor &
Commerce to which the following were referred, action taken on March
23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1330.
The committee roll call vote on SENATE BILL 1330 is as follows:
14, Yeas; 0, Nays; 0, Answering Present.
Y Stroger, Chair Y Johnson, Tom
Y Brady Y Jones, Shirley
Y Dart Y McKeon, V-Chair
Y Davis, Monique A Moore, Andrea
Y Harris Y Osmond
Y Hoeft A Parke, Spkpn
Y Howard Y Sharp
Y Hultgren A Slone
Y Winters
Representative Giles, Chairperson, from the Committee on Local
Government to which the following were referred, action taken on March
23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1294, 1376, 1377, 1504
and 1881.
The committee roll call vote on SENATE BILLS 1294, 1377, 1504, and
1881 is as follows:
9, Yeas; 0, Nays; 0, Answering Present.
Y Giles, Chair Y Mathias
Y Acevedo Y Mautino
Y Hartke Y Moffitt, Spkpn
Y Lawfer Y Scott
Y Skinner
The committee roll call vote on SENATE BILL 1376 is as follows:
8, Yeas; 1, Nays; 0, Answering Present.
Y Giles, Chair Y Mathias
Y Acevedo Y Mautino
N Hartke Y Moffitt, Spkpn
Y Lawfer Y Scott
Y Skinner
Representative Giles, Chairperson, from the Committee on Local
Government to which the following were referred, action taken earlier
today, and reported the same back with the following recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1477.
The committee roll call vote on SENATE BILL 1477 is as follows:
11 [March 24, 2000]
6, Yeas; 1, Nays; 0, Answering Present.
Y Giles, Chair A Mathias
Y Acevedo Y Mautino
Y Hartke Y Moffitt, Spkpn
N Lawfer Y Scott
A Skinner
Representative Saviano, Chairperson, from the Committee on
Registration & Regulation to which the following were referred, action
taken on March 23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1323 and 1404.
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILL 1339.
The committee roll call vote on SENATE BILLS 1323, 1339, and 1404
is as follows:
16, Yeas; 0, Nays; 0, Answering Present.
Y Saviano, Chair Y Klingler
Y Boland Y Kosel
Y Bradley Y Lyons, Eileen
Y Bugielski, V-Chair Y Meyer
Y Burke Y Mulligan
Y Coulson A Novak
Y Crotty Y Reitz
Y Davis, Steve Y Stephens
Y Zickus, Spkpn (Righter)
Representative Pugh, Chairperson, from the Committee on Revenue to
which the following were referred, action taken earlier today, and
reported the same back with the following recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 810, 1249, 1277, 1307,
1317, 1651, and 1674.
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILLS 334, 1296, 1303,
1304, 1627, 1645, 1693, 1707, 1899 and 1929.
The committee roll call vote on SENATE BILL 1883 is as follows:
5, Yeas; 4, Nays; 0, Answering Present.
Y Pugh, Chair Y Currie
N Beaubien Y Granberg
N Biggins Y Mautino, V-Chair
N Cross N Moore, Andrea, Spkpn
Y Turner, Art
The committee roll call vote on SENATE BILLS 334, 810, 1249, 1277,
1296, 1303, 1304, 1307, 1317, 1627, 1645, 1651, 1674, 1693, 1707, 1899,
and 1929. is as follows:
9, Yeas; 0, Nays; 0, Answering Present.
Y Pugh, Chair Y Currie
Y Beaubien Y Granberg
Y Biggins Y Mautino, V-Chair
Y Cross Y Moore, Andrea, Spkpn
Y Turner, Art
Representative Kenner, Chairperson, from the Committee on State
Government Administration to which the following were referred, action
taken on March 23, 2000, and reported the same back with the following
recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1291, 1734 and 1874.
That the bill be reported "do pass, as amended" and be placed on
[March 24, 2000] 12
the order of Second Reading -- Short Debate: SENATE BILLS 1513, 1540,
1659 and 1871.
The committee roll call vote on SENATE BILLS 1291, 1513, 1540,
1659, 1734, 1871, and 1874 is as follows:
9, Yeas; 0, Nays; 0, Answering Present.
Y Kenner, Chair Y Lang
Y Curry, Julie Y Mitchell, Bill
Y Feigenholtz Y O'Connor, Spkpn
Y Franks Y Schmitz
Y Sommer
Representative Fritchey, Chairperson, from the Committee on Tobacco
Settlement Proceeds Distribution to which the following were referred,
action taken on March 23, 2000, and reported the same back with the
following recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILL 1851.
The committee roll call vote on SENATE BILL 1851 is as follows:
18, Yeas; 0, Nays; 0, Answering Present.
Y Fritchey, Chair Y Krause
A Beaubien Y Mitchell, Bill, Spkpn
A Bellock A Moore, Andrea
Y Biggins Y Mulligan
A Boland Y Myers, Richard
Y Bost Y Novak
Y Coulson Y O'Connor
A Davis, Monique A Osterman
Y Durkin Y Pankau
A Feigenholtz, V-Chair Y Pugh
A Flowers Y Righter
A Garrett A Schoenberg
Y Gash A Scott
A Giles A Skinner
Y Hamos Y Slone
Y Hoffman A Zickus
Representative Hoffman, Chairperson, from the Committee on
Transportation & Motor Vehicles to which the following were referred,
action taken earlier today, and reported the same back with the
following recommendations:
That the bill be reported "do pass" and be placed on the order of
Second Reading -- Short Debate: SENATE BILLS 1298 and 1626.
That the bill be "tabled in Committee" pursuant to House Rule
22(g): SENATE BILL 1588.
The committee roll call vote on SENATE BILL 1298 is as follows:
19, Yeas; 9, Nays; 0, Answering Present.
Y Hoffman, Chair Y Lyons, Joseph
Y Bassi Y Mathias
Y Black Y McAuliffe
Y Brosnahan N Moffitt
Y Fowler N Myers, Richard
Y Garrett N O'Brien
Y Giglio, V-Chair (Morrow) Y Osterman
Y Hamos N Pankau
Y Harris N Reitz
N Hartke Y Schmitz
N Hassert Y Scully
Y Holbrook A Sharp
N Jones, John N Wait, Spkpn
Y Kosel Y Wojcik
Y Zickus (Winters)
The committee roll call vote on SENATE BILL 1626 is as follows:
13 [March 24, 2000]
17, Yeas; 9, Nays; 2, Answering Present.
Y Hoffman, Chair P Lyons, Joseph
Y Bassi Y Mathias
N Black N McAuliffe
Y Brosnahan Y Moffitt
Y Fowler Y Myers, Richard
Y Garrett N O'Brien
N Giglio, V-Chair (Morrow) Y Osterman
Y Hamos N Pankau
Y Harris N Reitz
N Hartke Y Schmitz
Y Hassert Y Scully
P Holbrook A Sharp
N Jones, John Y Wait, Spkpn
Y Kosel N Wojcik
Y Zickus (Winters)
Representative McCarthy, Chairperson, from the Committee on Urban
Revitalization to which the following were referred, action taken
earlier today, and reported the same back with the following
recommendations:
That the bill be reported "do pass as amended" and be placed on the
order of Second Reading -- Short Debate: SENATE BILL 1451.
The committee roll call vote on SENATE BILL 1451 is as follows:
12, Yeas; 0, Nays; 0, Answering Present.
A Scott, Chair Y McCarthy, V-Chair
Y Bassi Y McKeon
Y Dart Y O'Connor
Y Garrett Y Parke
Y Harris A Slone
Y Mathias, Spkpn Y Winters
Y McAuliffe A Younge
Y Zickus (Sommer)
MESSAGES FROM THE SENATE
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House in the passage of bills of
the following titles to-wit:
HOUSE BILL NO. 2580
A bill for AN ACT concerning higher education, amending named Acts.
HOUSE BILL NO. 2883
A bill for AN ACT to amend the Illinois Vehicle Code by changing
Sections 2-123, 6-204, and 16-104a.
HOUSE BILL NO. 2885
A bill for AN ACT to amend the Civil Administrative Code of
Illinois by changing Section 205-15.
HOUSE BILL NO. 3119
A bill for AN ACT amending the Good Samaritan Food Donor Act by
adding Section 2.14 and changing Section 3.
HOUSE BILL NO. 3131
A bill for AN ACT in concerning township plan commissions.
HOUSE BILL NO. 3558
A bill for AN ACT to amend the Abandoned Mined Lands and Water
[March 24, 2000] 14
Reclamation Act by changing Section 2.11.
HOUSE BILL NO. 3840
A bill for AN ACT to amend the School Code by changing Sections
34-2.1, 34-2.3, and 34-8.1.
HOUSE BILL NO. 4092
A bill for AN ACT concerning county officers.
HOUSE BILL NO. 4138
A bill for AN ACT to amend the Clerks of Courts Act by changing
Section 27.3b.
HOUSE BILL NO. 4266
A bill for AN ACT in relation to adult education.
Passed by the Senate, March 24, 2000.
Jim Harry, Secretary of the Senate
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House of Representatives in the
passage of a bill of the following title to-wit:
HOUSE BILL 486
A bill for AN ACT concerning kidney transplants.
Together with the attached amendment thereto (which amendment has
been printed by the Senate), in the adoption of which I am instructed
to ask the concurrence of the House, to-wit:
Senate Amendment No. 1 to HOUSE BILL NO. 486.
Passed the Senate, as amended, March 24, 2000.
Jim Harry, Secretary of the Senate
AMENDMENT NO. 1. Amend House Bill 486 as follows:
by replacing the title with the following:
"AN ACT concerning organ transplants."; and
by replacing everything after the enacting clause with the following:
"Section 5. The Civil Administrative Code of Illinois is amended
by adding Section 2310-260 as follows:
(20 ILCS 2310/2310-260 new)
Sec. 2310-260. Payments for post transplant maintenance and
retention.
(a) The Department shall establish and administer a program to pay
recipients for drugs and other costs prescribed exclusively for post
transplant maintenance and retention when those costs are not otherwise
reimbursed. The Department shall establish eligibility standards and an
application process by rule. Notwithstanding any other provision of
this Code to the contrary, the Department may, by rule, require
participants to pay a co-payment for the drugs covered under this
program.
(b) Participation in the program shall be limited to persons whose
household income is not greater than 400% of the federal poverty level
as established by the federal Office of Management and Budget. The
program shall be available only to eligible Illinois residents who have
resided in Illinois for at least 12 months; however, a person shall not
be excluded because that person received the transplant outside of the
State of Illinois.
15 [March 24, 2000]
(c) The Department shall pay a maximum amount per transplant
recipient based on the following:
(1) Available moneys in the Post Transplant Maintenance and
Retention Fund.
(2) Covered immunosuppressive drugs.
(3) The terms of any contract between the Department and the
provider.
The reimbursement rates shall be the same as the Medicaid
reimbursement rate for the drug, minus any co-payment and other medical
services.
(d) Payment shall be made under the program to or on behalf of a
program-eligible recipient only for costs not reimbursed or eligible
for reimbursement by any other third party or governmental entity,
including, without limitation, private or group insurance, Medicaid,
Medicare, and the Veterans Administration. The Director may, however,
waive this requirement in individually considered cases if the Director
determines that its enforcement will deny services to a class of post
transplant patients because of conflicting State or federal laws or
regulations.
(e) The Director may restrict or categorize reimbursements to meet
budgetary limitations.
(f) The Director shall maintain an immunosuppressive drug formulary
that shall include all drugs eligible for reimbursement by the program.
The Director shall establish an internal review procedure for updating
the formulary; the procedure shall allow the addition and deletion of
allowable drugs to the formulary. The internal review procedure shall
take place at least quarterly during a fiscal year.
(g) Payments made under the program established under this Section
shall be made, subject to appropriations, from the Post Transplant
Maintenance and Retention Fund, a special fund that is hereby created
in the State Treasury. The following shall be deposited into the Fund:
(i) amounts appropriated to the Department for that purpose, and (ii)
gifts, grants, and donations for that purpose from public and private
sources. Interest accruing on moneys in the Fund shall remain in the
Fund. Moneys in the Fund may be used only by the Department to make
payments for post transplant maintenance and retention under the
program established under this Section.
(h) Moneys remaining in the Post Transplant Maintenance and
Retention Fund at the end of the fiscal year may be used in the
following fiscal year.
Section 10. The State Finance Act is amended by adding Section
5.541 as follows:
(30 ILCS 105/5.541 new)
Sec. 5.541. The Post Transplant Maintenance and Retention Fund.
Section 99. Effective date. This Act takes effect on July 1,
2000.".
The foregoing message from the Senate reporting Senate Amendment
No. 1 to HOUSE BILL 486 was placed on the Calendar on the order of
Concurrence.
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House of Representatives in the
passage of a bill of the following title to-wit:
HOUSE BILL 2574
A bill for AN ACT to amend the Illinois Controlled Substances Act
by changing Sections 309, 312, and 406, by adding Sections 316, 317,
318, 319, and 320 and repealing Sections 308, 310, and 311.
Together with the attached amendments thereto (which amendments
have been printed by the Senate), in the adoption of which I am
instructed to ask the concurrence of the House, to-wit:
[March 24, 2000] 16
Senate Amendment No. 1 to HOUSE BILL NO. 2574.
Senate Amendment No. 3 to HOUSE BILL NO. 2574.
Senate Amendment No. 4 to HOUSE BILL NO. 2574.
Passed the Senate, as amended, March 24, 2000.
Jim Harry, Secretary of the Senate
AMENDMENT NO. 1. Amend House Bill 2574 as follows:
on page 1, lines 2 and 8, after "312," each time it appears, by
inserting "313,"; and
on page 2, line 1, by changing "a written" to "an oral"; and
on line 2, by replacing "72 hours" with "7 days 72 hours"; and
on line 12, by replacing "72-hour" with "7-day 72-hour"; and
on page 9, after line 7, by inserting the following:
"(720 ILCS 570/313) (from Ch. 56 1/2, par. 1313)
Sec. 313. (a) Controlled substances which are lawfully
administered in hospitals or institutions licensed under the "Hospital
Licensing Act" shall be exempt from the requirements of Sections 308
and 312 and 316 except that the prescription for the controlled
substance shall be in writing on the patient's record, signed by the
prescriber, dated, and shall state the name, and quantity of controlled
substances ordered and the quantity actually administered. The records
of such prescriptions shall be maintained for two years and shall be
available for inspection by officers and employees of the Department of
State Police, and the Department of Professional Regulation.
(b) Controlled substances that can lawfully be administered or
dispensed directly to a patient in a long-term care facility licensed
by the Department of Public Health as a skilled nursing facility,
intermediate care facility, or long-term care facility for residents
under 22 years of age, are exempt from the requirements of Sections 308
and 312 and 316. , except that a prescription for a Schedule II
controlled substance must be either a written prescription signed by
the prescriber or a written prescription transmitted by the prescriber
or prescriber's agent to the dispensing pharmacy by facsimile. The
facsimile serves as the original written prescription and must be
maintained for 2 years from the date of issue in the same manner as a
written prescription signed by the prescriber.
(c) (Blank). A prescription that is written for a Schedule II
controlled substance to be compounded for direct administration by
parenteral, intravenous, intramuscular, subcutaneous, or intraspinal
infusion to a patient in a private residence, long-term care facility,
or hospice setting may be transmitted by facsimile by the prescriber or
the prescriber's agent to the pharmacy providing the home infusion
services.
(d) Controlled substances which are lawfully administered and/or
dispensed in drug abuse treatment programs licensed by the Department
shall be exempt from the requirements of Sections 308 and 312 and 316,
except that the prescription for such controlled substances shall be
issued and authenticated on official prescription logs prepared and
supplied by the Department. The official prescription logs issued by
the Department shall be printed in triplicate on distinctively marked
paper and furnished to programs at reasonable cost. The official
prescription logs furnished to the programs shall contain, in
preprinted form, such information as the Department may require. The
official prescription logs shall be properly endorsed by a physician
licensed to practice medicine in all its branches issuing the order,
with his own signature and the date of ordering, and further endorsed
by the practitioner actually administering or dispensing the dosage at
the time of such administering or dispensing in accordance with
requirements issued by the Department. The duplicate copy shall be
retained by the program for a period of not less than three years nor
17 [March 24, 2000]
more than seven years; the original and triplicate copy shall be
returned to the Department at its principal office in accordance with
requirements set forth by the Department.
(Source: P.A. 89-202, eff. 10-1-95.)"; and
on line 9, by replacing "Controlled" with "Schedule II controlled"; and
on lines 11, 14, 19, 21, 22, and 31, before "controlled" each time it
appears, by inserting "Schedule II"; and
by deleting line 24; and
on line 25, by changing "(G)" to "(F)"; and
on line 27, by changing "(H)" to "(G)"; and
on page 10, after line 7, by inserting the following:
"Schedule II controlled substances are exempt from the requirements
of this Section to the extent provided in Section 313."; and
by deleting line 27; and
on line 28, by changing "(G)" to "(F)"; and
on line 30, by changing "(H)" to "(G)"; and
on page 11, line 2, by changing "shall" to "must" and by inserting
"electronic" before "access"; and
on page 14, line 17, before "controlled", by inserting "Schedule II";
and
on line 18, after the period, by inserting the following: "The
advisory committee shall consist of prescribers and dispensers."; and
on page 17, after line 9, by inserting the following:
"Section 99. Effective date. This Act takes effect April 1,
2000.".
AMENDMENT NO. 3. Amend House Bill 2574, AS AMENDED, by replacing
the title with the following:
"AN ACT to amend the Illinois Controlled Substances Act by changing
Sections 102, 201, 309, 312, 313, and 316."; and
by replacing everything after the enacting clause with the following:
"Section 5. The Illinois Controlled Substances Act is amended by
changing Sections 102, 201, 309, 312, 313, and 316 as follows:
(720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)
Sec. 102. Definitions. As used in this Act, unless the context
otherwise requires:
(a) "Addict" means any person who habitually uses any drug,
chemical, substance or dangerous drug other than alcohol so as to
endanger the public morals, health, safety or welfare or who is so far
addicted to the use of a dangerous drug or controlled substance other
than alcohol as to have lost the power of self control with reference
to his addiction.
(b) "Administer" means the direct application of a controlled
substance, whether by injection, inhalation, ingestion, or any other
means, to the body of a patient or research subject by:
(1) a practitioner (or, in his presence, by his authorized
agent), or
(2) the patient or research subject at the lawful direction
of the practitioner.
(c) "Agent" means an authorized person who acts on behalf of or at
the direction of a manufacturer, distributor, or dispenser. It does
not include a common or contract carrier, public warehouseman or
employee of the carrier or warehouseman.
(c-1) "Anabolic Steroids" means any drug or hormonal substance,
chemically and pharmacologically related to testosterone (other than
estrogens, progestins, and corticosteroids) that promotes muscle
growth, and includes:
(i) boldenone,
(ii) chlorotestosterone,
(iii) chostebol,
(iv) dehydrochlormethyltestosterone,
(v) dihydrotestosterone,
(vi) drostanolone,
(vii) ethylestrenol,
(viii) fluoxymesterone,
(ix) formebulone,
[March 24, 2000] 18
(x) mesterolone,
(xi) methandienone,
(xii) methandranone,
(xiii) methandriol,
(xiv) methandrostenolone,
(xv) methenolone,
(xvi) methyltestosterone,
(xvii) mibolerone,
(xviii) nandrolone,
(xix) norethandrolone,
(xx) oxandrolone,
(xxi) oxymesterone,
(xxii) oxymetholone,
(xxiii) stanolone,
(xxiv) stanozolol,
(xxv) testolactone,
(xxvi) testosterone,
(xxvii) trenbolone, and
(xxviii) any salt, ester, or isomer of a drug or
substance described or listed in this paragraph, if that salt,
ester, or isomer promotes muscle growth.
Any person who is otherwise lawfully in possession of an anabolic
steroid, or who otherwise lawfully manufactures, distributes,
dispenses, delivers, or possesses with intent to deliver an anabolic
steroid, which anabolic steroid is expressly intended for and lawfully
allowed to be administered through implants to livestock or other
nonhuman species, and which is approved by the Secretary of Health and
Human Services for such administration, and which the person intends to
administer or have administered through such implants, shall not be
considered to be in unauthorized possession or to unlawfully
manufacture, distribute, dispense, deliver, or possess with intent to
deliver such anabolic steroid for purposes of this Act.
(d) "Administration" means the Drug Enforcement Administration,
United States Department of Justice, or its successor agency.
(e) "Control" means to add a drug or other substance, or immediate
precursor, to a Schedule under Article II of this Act whether by
transfer from another Schedule or otherwise.
(f) "Controlled Substance" means a drug, substance, or immediate
precursor in the Schedules of Article II of this Act.
(g) "Counterfeit substance" means a controlled substance, which,
or the container or labeling of which, without authorization bears the
trademark, trade name, or other identifying mark, imprint, number or
device, or any likeness thereof, of a manufacturer, distributor, or
dispenser other than the person who in fact manufactured, distributed,
or dispensed the substance.
(h) "Deliver" or "delivery" means the actual, constructive or
attempted transfer of possession of a controlled substance, with or
without consideration, whether or not there is an agency relationship.
(i) "Department" means the Illinois Department of Human Services
(as successor to the Department of Alcoholism and Substance Abuse) or
its successor agency.
(j) "Department of State Police" means the Department of State
Police of the State of Illinois or its successor agency.
(k) "Department of Corrections" means the Department of
Corrections of the State of Illinois or its successor agency.
(l) "Department of Professional Regulation" means the Department
of Professional Regulation of the State of Illinois or its successor
agency.
(m) "Depressant" or "stimulant substance" means:
(1) a drug which contains any quantity of (i) barbituric acid
or any of the salts of barbituric acid which has been designated as
habit forming under section 502 (d) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 352 (d)); or
(2) a drug which contains any quantity of (i) amphetamine or
methamphetamine and any of their optical isomers; (ii) any salt of
amphetamine or methamphetamine or any salt of an optical isomer of
19 [March 24, 2000]
amphetamine; or (iii) any substance which the Department, after
investigation, has found to be, and by rule designated as, habit
forming because of its depressant or stimulant effect on the
central nervous system; or
(3) lysergic acid diethylamide; or
(4) any drug which contains any quantity of a substance which
the Department, after investigation, has found to have, and by rule
designated as having, a potential for abuse because of its
depressant or stimulant effect on the central nervous system or its
hallucinogenic effect.
(n) (Blank). "Designated product" means any narcotic drug,
amphetamine, phenmetrazine, methamphetamine, gluthethimide, pentazocine
or cannabis product listed in Schedule II and also means a controlled
substance listed in Schedule II which is determined and designated by
the Department or its successor agency to be such a product. A
designated product shall only be dispensed upon an official
prescription blank.
(o) "Director" means the Director of the Department of State
Police or the Department of Professional Regulation or his designated
agents.
(p) "Dispense" means to deliver a controlled substance to an
ultimate user or research subject by or pursuant to the lawful order of
a prescriber, including the prescribing, administering, packaging,
labeling, or compounding necessary to prepare the substance for that
delivery.
(q) "Dispenser" means a practitioner who dispenses.
(r) "Distribute" means to deliver, other than by administering or
dispensing, a controlled substance.
(s) "Distributor" means a person who distributes.
(t) "Drug" means (1) substances recognized as drugs in the
official United States Pharmacopoeia, Official Homeopathic
Pharmacopoeia of the United States, or official National Formulary, or
any supplement to any of them; (2) substances intended for use in
diagnosis, cure, mitigation, treatment, or prevention of disease in man
or animals; (3) substances (other than food) intended to affect the
structure of any function of the body of man or animals and (4)
substances intended for use as a component of any article specified in
clause (1), (2), or (3) of this subsection. It does not include
devices or their components, parts, or accessories.
(u) "Good faith" means the prescribing or dispensing of a
controlled substance by a practitioner in the regular course of
professional treatment to or for any person who is under his treatment
for a pathology or condition other than that individual's physical or
psychological dependence upon or addiction to a controlled substance,
except as provided herein: and application of the term to a pharmacist
shall mean the dispensing of a controlled substance pursuant to the
prescriber's order which in the professional judgment of the pharmacist
is lawful. The pharmacist shall be guided by accepted professional
standards including, but not limited to the following, in making the
judgment:
(1) lack of consistency of doctor-patient relationship,
(2) frequency of prescriptions for same drug by one
prescriber for large numbers of patients,
(3) quantities beyond those normally prescribed,
(4) unusual dosages,
(5) unusual geographic distances between patient, pharmacist
and prescriber,
(6) consistent prescribing of habit-forming drugs.
(u-1) "Home infusion services" means services provided by a
pharmacy in compounding solutions for direct administration to a
patient in a private residence, long-term care facility, or hospice
setting by means of parenteral, intravenous, intramuscular,
subcutaneous, or intraspinal infusion.
(v) "Immediate precursor" means a substance:
(1) which the Department has found to be and by rule
designated as being a principal compound used, or produced
[March 24, 2000] 20
primarily for use, in the manufacture of a controlled substance;
(2) which is an immediate chemical intermediary used or
likely to be used in the manufacture of such controlled substance;
and
(3) the control of which is necessary to prevent, curtail or
limit the manufacture of such controlled substance.
(w) "Instructional activities" means the acts of teaching,
educating or instructing by practitioners using controlled substances
within educational facilities approved by the State Board of Education
or its successor agency.
(x) "Local authorities" means a duly organized State, County or
Municipal peace unit or police force.
(y) "Look-alike substance" means a substance, other than a
controlled substance which (1) by overall dosage unit appearance,
including shape, color, size, markings or lack thereof, taste,
consistency, or any other identifying physical characteristic of the
substance, would lead a reasonable person to believe that the substance
is a controlled substance, or (2) is expressly or impliedly represented
to be a controlled substance or is distributed under circumstances
which would lead a reasonable person to believe that the substance is a
controlled substance. For the purpose of determining whether the
representations made or the circumstances of the distribution would
lead a reasonable person to believe the substance to be a controlled
substance under this clause (2) of subsection (y), the court or other
authority may consider the following factors in addition to any other
factor that may be relevant:
(a) statements made by the owner or person in control of the
substance concerning its nature, use or effect;
(b) statements made to the buyer or recipient that the
substance may be resold for profit;
(c) whether the substance is packaged in a manner normally
used for the illegal distribution of controlled substances;
(d) whether the distribution or attempted distribution
included an exchange of or demand for money or other property as
consideration, and whether the amount of the consideration was
substantially greater than the reasonable retail market value of
the substance.
Clause (1) of this subsection (y) shall not apply to a
noncontrolled substance in its finished dosage form that was initially
introduced into commerce prior to the initial introduction into
commerce of a controlled substance in its finished dosage form which it
may substantially resemble.
Nothing in this subsection (y) prohibits the dispensing or
distributing of noncontrolled substances by persons authorized to
dispense and distribute controlled substances under this Act, provided
that such action would be deemed to be carried out in good faith under
subsection (u) if the substances involved were controlled substances.
Nothing in this subsection (y) or in this Act prohibits the
manufacture, preparation, propagation, compounding, processing,
packaging, advertising or distribution of a drug or drugs by any person
registered pursuant to Section 510 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360).
(y-1) "Mail-order pharmacy" means a pharmacy that is located in a
state of the United States, other than Illinois, that delivers,
dispenses or distributes, through the United States Postal Service or
other common carrier, to Illinois residents, any substance which
requires a prescription.
(z) "Manufacture" means the production, preparation, propagation,
compounding, conversion or processing of a controlled substance, either
directly or indirectly, by extraction from substances of natural
origin, or independently by means of chemical synthesis, or by a
combination of extraction and chemical synthesis, and includes any
packaging or repackaging of the substance or labeling of its container,
except that this term does not include:
(1) by an ultimate user, the preparation or compounding of a
controlled substance for his own use; or
21 [March 24, 2000]
(2) by a practitioner, or his authorized agent under his
supervision, the preparation, compounding, packaging, or labeling
of a controlled substance:
(a) as an incident to his administering or dispensing of
a controlled substance in the course of his professional
practice; or
(b) as an incident to lawful research, teaching or
chemical analysis and not for sale.
(z-1) "Methamphetamine manufacturing chemical" means any of the
following chemicals or substances containing any of the following
chemicals: benzyl methyl ketone, ephedrine, methyl benzyl ketone,
phenylacetone, phenyl-2-propanone, or pseudoephedrine or any of the
salts, optical isomers, or salts of optical isomers of the above-listed
chemicals.
(aa) "Narcotic drug" means any of the following, whether produced
directly or indirectly by extraction from substances of natural origin,
or independently by means of chemical synthesis, or by a combination of
extraction and chemical synthesis:
(1) opium and opiate, and any salt, compound, derivative, or
preparation of opium or opiate;
(2) any salt, compound, isomer, derivative, or preparation
thereof which is chemically equivalent or identical with any of the
substances referred to in clause (1), but not including the
isoquinoline alkaloids of opium;
(3) opium poppy and poppy straw;
(4) coca leaves and any salts, compound, isomer, salt of an
isomer, derivative, or preparation of coca leaves including cocaine
or ecgonine, and any salt, compound, isomer, derivative, or
preparation thereof which is chemically equivalent or identical
with any of these substances, but not including decocainized coca
leaves or extractions of coca leaves which do not contain cocaine
or ecgonine (for the purpose of this paragraph, the term "isomer"
includes optical, positional and geometric isomers).
(bb) "Nurse" means a registered nurse licensed under the Nursing
and Advanced Practice Nursing Act.
(cc) (Blank). "Official prescription blanks" means the triplicate
prescription forms supplied to prescribers by the Department for
prescribing Schedule II Designated Product controlled substances.
(dd) "Opiate" means any substance having an addiction forming or
addiction sustaining liability similar to morphine or being capable of
conversion into a drug having addiction forming or addiction sustaining
liability.
(ee) "Opium poppy" means the plant of the species Papaver
somniferum L., except its seeds.
(ff) "Parole and Pardon Board" means the Parole and Pardon Board
of the State of Illinois or its successor agency.
(gg) "Person" means any individual, corporation, mail-order
pharmacy, government or governmental subdivision or agency, business
trust, estate, trust, partnership or association, or any other entity.
(hh) "Pharmacist" means any person who holds a certificate of
registration as a registered pharmacist, a local registered pharmacist
or a registered assistant pharmacist under the Pharmacy Practice Act of
1987.
(ii) "Pharmacy" means any store, ship or other place in which
pharmacy is authorized to be practiced under the Pharmacy Practice Act
of 1987.
(jj) "Poppy straw" means all parts, except the seeds, of the opium
poppy, after mowing.
(kk) "Practitioner" means a physician licensed to practice
medicine in all its branches, dentist, podiatrist, veterinarian,
scientific investigator, pharmacist, physician assistant, advanced
practice nurse, licensed practical nurse, registered nurse, hospital,
laboratory, or pharmacy, or other person licensed, registered, or
otherwise lawfully permitted by the United States or this State to
distribute, dispense, conduct research with respect to, administer or
use in teaching or chemical analysis, a controlled substance in the
[March 24, 2000] 22
course of professional practice or research.
(ll) "Pre-printed prescription" means a written prescription upon
which the designated drug has been indicated prior to the time of
issuance.
(mm) "Prescriber" means a physician licensed to practice medicine
in all its branches, dentist, podiatrist or veterinarian who issues a
prescription, a physician assistant who issues a prescription for a
Schedule III, IV, or V controlled substance in accordance with Section
303.05 and the written guidelines required under Section 7.5 of the
Physician Assistant Practice Act of 1987, or an advanced practice nurse
with prescriptive authority in accordance with Section 303.05 and a
written collaborative agreement under Sections 15-15 and 15-20 of the
Nursing and Advanced Practice Nursing Act.
(nn) "Prescription" means a lawful written, facsimile, or verbal
order of a physician licensed to practice medicine in all its branches,
dentist, podiatrist or veterinarian for any controlled substance, of a
physician assistant for a Schedule III, IV, or V controlled substance
in accordance with Section 303.05 and the written guidelines required
under Section 7.5 of the Physician Assistant Practice Act of 1987, or
of an advanced practice nurse who issues a prescription for a Schedule
III, IV, or V controlled substance in accordance with Section 303.05
and a written collaborative agreement under Sections 15-15 and 15-20 of
the Nursing and Advanced Practice Nursing Act.
(oo) "Production" or "produce" means manufacture, planting,
cultivating, growing, or harvesting of a controlled substance.
(pp) "Registrant" means every person who is required to register
under Section 302 of this Act.
(qq) "Registry number" means the number assigned to each person
authorized to handle controlled substances under the laws of the United
States and of this State.
(rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof, and any
area subject to the legal authority of the United States of America.
(ss) "Ultimate user" means a person who lawfully possesses a
controlled substance for his own use or for the use of a member of his
household or for administering to an animal owned by him or by a member
of his household.
(Source: P.A. 90-116, eff. 7-14-97; 90-742, eff. 8-13-98; 90-818, eff.
3-23-99; 91-403, eff. 1-1-00.)
(720 ILCS 570/201) (from Ch. 56 1/2, par. 1201)
Sec. 201. (a) The Department shall carry out the provisions of
this Article. The Department or its successor agency may add
substances to or delete or reschedule all controlled substances in the
Schedules of Sections 204, 206, 208, 210 and 212 of this Act and shall
determine "designated products" as required under Sections 308, 309,
311 and 312 of this Act. In making a determination regarding the
addition, deletion, or rescheduling of a substance, the Department
shall consider the following:
(1) the actual or relative potential for abuse;
(2) the scientific evidence of its pharmacological effect, if
known;
(3) the state of current scientific knowledge regarding the
substance;
(4) the history and current pattern of abuse;
(5) the scope, duration, and significance of abuse;
(6) the risk to the public health;
(7) the potential of the substance to produce psychological or
physiological dependence;
(8) whether the substance is an immediate precursor of a substance
already controlled under this Article;
(9) the immediate harmful effect in terms of potentially fatal
dosage; and
(10) the long-range effects in terms of permanent health
impairment.
(b) (Blank). In making a determination regarding a "designated
product," the Department shall consider the above criteria, and in
23 [March 24, 2000]
addition shall consider whether use of the official prescription blank
is required to control significant actual illicit traffic of the
substance.
After considering the factors enumerated in subsection (a) or in
the case of making a determination of a "designated product," the
additional factors of subsection (b), the Department shall publish its
determination. If, within 30 days from such publication, a party
adversely affected files with the Department substantial written
objections to inclusion, rescheduling, or deletion of a substance, or
to a determination of a "designated product," the Department shall
publish the substantial written objections and afford all interested
parties an opportunity to be heard. At the conclusion of the hearing,
the Department shall make findings with respect thereto and issue a
rule controlling the substance if the Department has determined that
the substance has a potential for abuse and submits to the General
Assembly a written report of its findings with respect thereto. Each
such rule adding, deleting or rescheduling a controlled substance or
determining a "designated product" shall then be submitted to the
General Assembly, in the form of a proposed law amending this Act, and
unless the proposed law is adopted by the General Assembly and enacted
into law within 2 years after the Department has issued the rule, such
rule shall expire and have no further force and effect.
The requirement for reporting to the General Assembly shall be
satisfied by filing copies of the report with the Speaker, the minority
Leader and the Clerk of the House of Representatives and the President,
the Minority Leader and the Secretary of the Senate and the Legislative
Research Unit, as required by Section 3.1 of "An Act to revise the law
in relation to the General Assembly", approved February 25, 1874, as
amended, and filing such additional copies with the State Government
Report Distribution Center for the General Assembly as is required
under paragraph (t) of Section 7 of the State Library Act.
(c) (Blank). If the Department designates a substance as an
immediate precursor, substances which are precursors of the controlled
precursor shall not be subject to control solely because they are
precursors of the controlled precursor.
(d) If any substance is scheduled designated, rescheduled, or
deleted as a controlled substance under Federal law and notice thereof
is given to the Department, the Department shall similarly control the
substance under this Act after the expiration of 30 days from
publication in the Federal Register of a final order scheduling
designating a substance as a controlled substance or rescheduling or
deleting a substance, unless within that 30 day period the Department
objects, or a party adversely affected files with the Department
substantial written objections objecting to inclusion, rescheduling, or
deletion. In that case, the Department shall publish the reasons for
objection or the substantial written objections and afford all
interested parties an opportunity to be heard. At the conclusion of
the hearing, the Department shall publish its decision, by means of a
rule, which shall be final unless altered by statute. Upon publication
of objections by the Department, similar control under this Act
whether by inclusion, rescheduling or deletion is stayed until the
Department publishes its ruling.
(e) The Department shall by rule exclude any non-narcotic
substances from a schedule if such substance may, under the Federal
Food, Drug, and Cosmetic Act, be lawfully sold over the counter without
a prescription.
(f) Dextromethorphan shall not be deemed to be included in any
schedule by reason of enactment of this title unless controlled after
the date of such enactment pursuant to the foregoing provisions of this
section.
(g) Authority to control under this section does not extend to
distilled spirits, wine, malt beverages, or tobacco as those terms are
defined or used in The Liquor Control Act and the Tobacco Products Tax
Act.
(Source: P.A. 84-1438.)
(720 ILCS 570/309) (from Ch. 56 1/2, par. 1309)
[March 24, 2000] 24
(Text of Section before amendment by P.A. 91-576)
Sec. 309. No person shall issue a prescription for a Schedule II
controlled substance, which is a narcotic drug listed in Section 206 of
this Act; or which contains any quantity of amphetamine or
methamphetamine, their salts, optical isomers or salts of optical
isomers; phenmetrazine and its salts; gluthethimide; pentazocine; or
which is hereafter determined to be a "designated product," as defined
in Section 102 of this Act, other than on the official prescription
blank issued by the Department and no person shall fill any such
prescription other than on the official prescription blank issued by
the Department; provided that in the case of an emergency, epidemic or
a sudden or unforeseen accident or calamity, the prescriber may issue a
lawful oral prescription or transmit via facsimile equipment a written
prescription order or a written prescription on a blank other than the
official prescription blank issued by the Department where failure to
issue such a prescription might result in loss of life or intense
suffering, but such prescription shall have endorsed thereon by the
prescriber a statement concerning the accident or calamity, or
circumstances constituting the emergency, the cause for which the
unofficial blank was used. Within 72 hours after issuing an emergency
prescription, the prescriber shall cause a written prescription on the
official prescription blank for the emergency quantity prescribed to be
delivered to the dispensing pharmacist. The prescription shall have
written on its face "Authorization for Emergency Dispensing", and the
date of the emergency prescription. The written prescription on the
official prescription blank may be delivered to the pharmacist in
person or by mail, but if delivered by mail it must be postmarked
within the 72-hour period. Upon receipt, the dispensing pharmacist
shall attach this prescription to the emergency prescription earlier
received, or in the case of an oral prescription, reduced to writing.
The dispensing pharmacist shall notify the Department of Human Services
if the prescriber fails to deliver the authorization for emergency
dispensing on the official prescription blank to him. Failure of the
dispensing pharmacist to do so shall void the authority conferred by
this paragraph to dispense without a written prescription on an
official prescription blank of a prescriber. All prescriptions on the
official blanks shall be written in triplicate and all three copies
signed by the prescriber. All prescriptions issued for Schedule II
controlled substances shall include both a written and numerical
notation of quantity on the face of the prescription. No prescription
for a Schedule II controlled substance may be refilled.
(Source: P.A. 89-202, eff. 10-1-95; 89-507, eff. 7-1-97.)
(Text of Section after amendment by P.A. 91-576)
Sec. 309. On or after April 1, 2000, no person shall issue a
prescription for a Schedule II controlled substance, which is a
narcotic drug listed in Section 206 of this Act; or which contains any
quantity of amphetamine or methamphetamine, their salts, optical
isomers or salts of optical isomers; phenmetrazine and its salts;
gluthethimide; and pentazocine; or which is hereafter determined to be
a "designated product," as defined in Section 102 of this Act, other
than on a written prescription; provided that in the case of an
emergency, epidemic or a sudden or unforeseen accident or calamity, the
prescriber may issue a lawful oral prescription where failure to issue
such a prescription might result in loss of life or intense suffering,
but such oral prescription shall include a statement by the prescriber
concerning the accident or calamity, or circumstances constituting the
emergency, the cause for which an oral prescription was used. Within 7
days after issuing an emergency prescription, the prescriber shall
cause a written prescription for the emergency quantity prescribed to
be delivered to the dispensing pharmacist. The prescription shall have
written on its face "Authorization for Emergency Dispensing", and the
date of the emergency prescription. The written prescription may be
delivered to the pharmacist in person, or by mail or via facsimile
equipment, but if delivered by mail it must be postmarked within the
7-day period. Upon receipt, the dispensing pharmacist shall attach this
prescription to the emergency oral prescription earlier received and
25 [March 24, 2000]
reduced to writing. The dispensing pharmacist shall notify the
Department of Human Services if the prescriber fails to deliver the
authorization for emergency dispensing on the prescription to him.
Failure of the dispensing pharmacist to do so shall void the authority
conferred by this paragraph to dispense without a written prescription
of a prescriber. All prescriptions issued for Schedule II controlled
substances shall include both a written and numerical notation of
quantity on the face of the prescription. No prescription for a
Schedule II controlled substance may be refilled.
(Source: P.A. 91-576, eff. 4-1-00.)
(720 ILCS 570/312) (from Ch. 56 1/2, par. 1312)
(Text of Section before amendment by P.A. 91-576)
Sec. 312. Requirements for dispensing controlled substances.
(a) A practitioner, in good faith, may dispense a Schedule II
controlled substance, which is a narcotic drug listed in Section 206 of
this Act; or which contains any quantity of amphetamine or
methamphetamine, their salts, optical isomers or salts of optical
isomers; phenmetrazine and its salts; pentazocine; or which is
hereafter determined to be a "designated product," as defined in
Section 102 of this Act to any person upon an official prescription
form and Schedule III, IV, or V controlled substances to any person
upon a written prescription of any prescriber, dated and signed by the
person prescribing on the day when issued and bearing the name and
address of the patient for whom, or the owner of the animal for which
the controlled substance is dispensed, and the full name, address and
registry number under the laws of the United States relating to
controlled substances of the prescriber, if he is required by those
laws to be registered. If the prescription is for an animal it shall
state the species of animal for which it is ordered. The practitioner
filling the prescription shall write the date of filling and his own
signature on the face of the official prescription form. The official
prescription form or the written prescription shall be retained on file
by the practitioner who filled it or pharmacy in which the prescription
was filled for a period of 2 years, so as to be readily accessible for
inspection or removal by any officer or employee engaged in the
enforcement of this Act. Whenever the practitioner's or pharmacy's
copy of any prescription form is removed by an officer or employee
engaged in the enforcement of this Act, for the purpose of
investigation or as evidence, such officer or employee shall give to
the practitioner or pharmacy a receipt in lieu thereof. A prescription
form for a Schedule II controlled substance shall not be filled more
than 7 days after the date of issuance. A written prescription for
Schedule III, IV or V controlled substances shall not be filled or
refilled more than 6 months after the date thereof or refilled more
than 5 times unless renewed, in writing, by the prescriber.
(b) In lieu of a written prescription required by this Section, a
pharmacist, in good faith, may dispense Schedule III, IV, or V
substances to any person either upon receiving a facsimile of a
written, signed prescription transmitted by the prescriber or the
prescriber's agent or upon a lawful oral prescription of a prescriber
which oral prescription shall be reduced promptly to writing by the
pharmacist and such written memorandum thereof shall be dated on the
day when such oral prescription is received by the pharmacist and shall
bear the full name and address of the ultimate user for whom, or of the
owner of the animal for which the controlled substance is dispensed,
and the full name, address, and registry number under the law of the
United States relating to controlled substances of the prescriber
prescribing if he is required by those laws to be so registered, and
the pharmacist filling such oral prescription shall write the date of
filling and his own signature on the face of such written memorandum
thereof. The facsimile copy of the prescription or written memorandum
of the oral prescription shall be retained on file by the proprietor of
the pharmacy in which it is filled for a period of not less than two
years, so as to be readily accessible for inspection by any officer or
employee engaged in the enforcement of this Act in the same manner as a
written prescription. The facsimile copy of the prescription or oral
[March 24, 2000] 26
prescription and the written memorandum thereof shall not be filled or
refilled more than 6 months after the date thereof or be refilled more
than 5 times, unless renewed, in writing, by the prescriber.
(c) A controlled substance included in Schedule V shall not be
distributed or dispensed other than for a medical purpose and not for
the purpose of evading this Act, and then:
(1) only personally by a person registered to dispense a
Schedule V controlled substance and then only to his patients, or
(2) only personally by a pharmacist, and then only to a
person over 21 years of age who has identified himself to the
pharmacist by means of 2 positive documents of identification.
(3) the dispenser shall record the name and address of the
purchaser, the name and quantity of the product, the date and time
of the sale, and the dispenser's signature.
(4) no person shall purchase or be dispensed more than 120
milliliters or more than 120 grams of any Schedule V substance
which contains codeine, dihydrocodeine, or any salts thereof, or
ethylmorphine, or any salts thereof, in any 96 hour period. The
purchaser shall sign a form, approved by the Department of
Professional Regulation, attesting that he has not purchased any
Schedule V controlled substances within the immediately preceding
96 hours.
(5) a copy of the records of sale, including all information
required by paragraph (3), shall be forwarded to the Department of
Professional Regulation at its principal office by the 15th day of
the following month.
(6) all records of purchases and sales shall be maintained
for not less than 2 years.
(7) no person shall obtain or attempt to obtain within any
consecutive 96 hour period any Schedule V substances of more than
120 milliliters or more than 120 grams containing codeine,
dihydrocodeine or any of its salts, or ethylmorphine or any of its
salts. Any person obtaining any such preparations or combination
of preparations in excess of this limitation shall be in unlawful
possession of such controlled substance.
(8) a person qualified to dispense controlled substances
under this Act and registered thereunder shall at no time maintain
or keep in stock a quantity of Schedule V controlled substances
defined and listed in Section 212 (b) (1), (2) or (3) in excess of
4.5 liters for each substance; a pharmacy shall at no time maintain
or keep in stock a quantity of Schedule V controlled substances as
defined in excess of 4.5 liters for each substance, plus the
additional quantity of controlled substances necessary to fill the
largest number of prescription orders filled by that pharmacy for
such controlled substances in any one week in the previous year.
These limitations shall not apply to Schedule V controlled
substances which Federal law prohibits from being dispensed without
a prescription.
(9) no person shall distribute or dispense butyl nitrite for
inhalation or other introduction into the human body for euphoric
or physical effect.
(d) Every practitioner shall keep a record of controlled
substances received by him and a record of all such controlled
substances administered, dispensed or professionally used by him
otherwise than by prescription. It shall, however, be sufficient
compliance with this paragraph if any practitioner utilizing controlled
substances listed in Schedules III, IV and V shall keep a record of all
those substances dispensed and distributed by him other than those
controlled substances which are administered by the direct application
of a controlled substance, whether by injection, inhalation, ingestion,
or any other means to the body of a patient or research subject. A
practitioner who dispenses, other than by administering, a controlled
substance in Schedule II, which is a narcotic drug listed in Section
206 of this Act, or which contains any quantity of amphetamine or
methamphetamine, their salts, optical isomers or salts of optical
isomers, pentazocine, methaqualone, or which is hereafter determined to
27 [March 24, 2000]
be a "designated product" as defined in Section 102 of this Act, shall
do so only upon the issuance of an official prescription blank by a
prescriber; and every practitioner who so dispenses such designated
products shall comply with the provisions of Sections 310 and 311 of
this Act.
(e) Whenever a manufacturer distributes a controlled substance in
a package prepared by him, and whenever a wholesale distributor
distributes a controlled substance in a package prepared by him or the
manufacturer, he shall securely affix to each package in which that
substance is contained a label showing in legible English the name and
address of the manufacturer, the distributor and the quantity, kind and
form of controlled substance contained therein. No person except a
pharmacist and only for the purposes of filling a prescription under
this Act, shall alter, deface or remove any label so affixed.
(f) Whenever a practitioner dispenses any controlled substance, he
shall affix to the container in which such substance is sold or
dispensed, a label indicating the date of initial filling, the
practitioner's name and address, the serial number of the prescription,
the name of the patient, the name of the prescriber, the directions for
use and cautionary statements, if any, contained in any prescription or
required by law, the proprietary name or names or the established name
of the controlled substance, and the dosage and quantity, except as
otherwise authorized by regulation by the Department of Professional
Regulation. No person shall alter, deface or remove any label so
affixed.
(g) A person to whom or for whose use any controlled substance has
been prescribed or dispensed by a practitioner, or other persons
authorized under this Act, and the owner of any animal for which such
substance has been prescribed or dispensed by a veterinarian, may
lawfully possess such substance only in the container in which it was
delivered to him by the person dispensing such substance.
(h) The responsibility for the proper prescribing or dispensing of
controlled substances is upon the prescriber and the responsibility for
the proper filling of a prescription for controlled substance drugs
rests with the pharmacist. An order purporting to be a prescription
issued to any individual, which is not in the regular course of
professional treatment nor part of an authorized methadone maintenance
program, nor in legitimate and authorized research instituted by any
accredited hospital, educational institution, charitable foundation, or
federal, state or local governmental agency, and which is intended to
provide that individual with controlled substances sufficient to
maintain that individual's or any other individual's physical or
psychological addiction, habitual or customary use, dependence, or
diversion of that controlled substance is not a prescription within the
meaning and intent of this Act; and the person issuing it, shall be
subject to the penalties provided for violations of the law relating to
controlled substances.
(i) A prescriber shall not preprint or cause to be preprinted a
prescription for any controlled substance; nor shall any practitioner
issue, fill or cause to be issued or filled, a preprinted prescription
for any controlled substance.
(j) No person shall manufacture, dispense, deliver, possess with
intent to deliver, prescribe, or administer or cause to be administered
under his direction any anabolic steroid, for any use in humans other
than the treatment of disease in accordance with the order of a
physician licensed to practice medicine in all its branches for a valid
medical purpose in the course of professional practice. The use of
anabolic steroids for the purpose of hormonal manipulation that is
intended to increase muscle mass, strength or weight without a medical
necessity to do so, or for the intended purpose of improving physical
appearance or performance in any form of exercise, sport, or game, is
not a valid medical purpose or in the course of professional practice.
(Source: P.A. 89-202, eff. 10-1-95; 90-253, eff. 7-29-97.)
(Text of Section after amendment by P.A. 91-576)
Sec. 312. Requirements for dispensing controlled substances.
(a) A practitioner, in good faith, may dispense a Schedule II
[March 24, 2000] 28
controlled substance, which is a narcotic drug listed in Section 206 of
this Act; or which contains any quantity of amphetamine or
methamphetamine, their salts, optical isomers or salts of optical
isomers; phenmetrazine and its salts; or pentazocine; or which is
hereafter determined to be a "designated product," as defined in
Section 102 of this Act and Schedule III, IV, or V controlled
substances to any person upon a written prescription of any prescriber,
dated and signed by the person prescribing on the day when issued and
bearing the name and address of the patient for whom, or the owner of
the animal for which the controlled substance is dispensed, and the
full name, address and registry number under the laws of the United
States relating to controlled substances of the prescriber, if he is
required by those laws to be registered. If the prescription is for an
animal it shall state the species of animal for which it is ordered.
The practitioner filling the prescription shall write the date of
filling and his own signature on the face of the written prescription.
The written prescription shall be retained on file by the practitioner
who filled it or pharmacy in which the prescription was filled for a
period of 2 years, so as to be readily accessible for inspection or
removal by any officer or employee engaged in the enforcement of this
Act. Whenever the practitioner's or pharmacy's copy of any
prescription is removed by an officer or employee engaged in the
enforcement of this Act, for the purpose of investigation or as
evidence, such officer or employee shall give to the practitioner or
pharmacy a receipt in lieu thereof. A prescription form for a Schedule
II controlled substance shall not be filled more than 7 days after the
date of issuance. A written prescription for Schedule III, IV or V
controlled substances shall not be filled or refilled more than 6
months after the date thereof or refilled more than 5 times unless
renewed, in writing, by the prescriber.
(b) In lieu of a written prescription required by this Section, a
pharmacist, in good faith, may dispense Schedule III, IV, or V
substances to any person either upon receiving a facsimile of a
written, signed prescription transmitted by the prescriber or the
prescriber's agent or upon a lawful oral prescription of a prescriber
which oral prescription shall be reduced promptly to writing by the
pharmacist and such written memorandum thereof shall be dated on the
day when such oral prescription is received by the pharmacist and shall
bear the full name and address of the ultimate user for whom, or of the
owner of the animal for which the controlled substance is dispensed,
and the full name, address, and registry number under the law of the
United States relating to controlled substances of the prescriber
prescribing if he is required by those laws to be so registered, and
the pharmacist filling such oral prescription shall write the date of
filling and his own signature on the face of such written memorandum
thereof. The facsimile copy of the prescription or written memorandum
of the oral prescription shall be retained on file by the proprietor of
the pharmacy in which it is filled for a period of not less than two
years, so as to be readily accessible for inspection by any officer or
employee engaged in the enforcement of this Act in the same manner as a
written prescription. The facsimile copy of the prescription or oral
prescription and the written memorandum thereof shall not be filled or
refilled more than 6 months after the date thereof or be refilled more
than 5 times, unless renewed, in writing, by the prescriber.
(c) A controlled substance included in Schedule V shall not be
distributed or dispensed other than for a medical purpose and not for
the purpose of evading this Act, and then:
(1) only personally by a person registered to dispense a
Schedule V controlled substance and then only to his patients, or
(2) only personally by a pharmacist, and then only to a
person over 21 years of age who has identified himself to the
pharmacist by means of 2 positive documents of identification.
(3) the dispenser shall record the name and address of the
purchaser, the name and quantity of the product, the date and time
of the sale, and the dispenser's signature.
(4) no person shall purchase or be dispensed more than 120
29 [March 24, 2000]
milliliters or more than 120 grams of any Schedule V substance
which contains codeine, dihydrocodeine, or any salts thereof, or
ethylmorphine, or any salts thereof, in any 96 hour period. The
purchaser shall sign a form, approved by the Department of
Professional Regulation, attesting that he has not purchased any
Schedule V controlled substances within the immediately preceding
96 hours.
(5) a copy of the records of sale, including all information
required by paragraph (3), shall be forwarded to the Department of
Professional Regulation at its principal office by the 15th day of
the following month.
(6) all records of purchases and sales shall be maintained
for not less than 2 years.
(7) no person shall obtain or attempt to obtain within any
consecutive 96 hour period any Schedule V substances of more than
120 milliliters or more than 120 grams containing codeine,
dihydrocodeine or any of its salts, or ethylmorphine or any of its
salts. Any person obtaining any such preparations or combination
of preparations in excess of this limitation shall be in unlawful
possession of such controlled substance.
(8) a person qualified to dispense controlled substances
under this Act and registered thereunder shall at no time maintain
or keep in stock a quantity of Schedule V controlled substances
defined and listed in Section 212 (b) (1), (2) or (3) in excess of
4.5 liters for each substance; a pharmacy shall at no time maintain
or keep in stock a quantity of Schedule V controlled substances as
defined in excess of 4.5 liters for each substance, plus the
additional quantity of controlled substances necessary to fill the
largest number of prescription orders filled by that pharmacy for
such controlled substances in any one week in the previous year.
These limitations shall not apply to Schedule V controlled
substances which Federal law prohibits from being dispensed without
a prescription.
(9) no person shall distribute or dispense butyl nitrite for
inhalation or other introduction into the human body for euphoric
or physical effect.
(d) Every practitioner shall keep a record of controlled
substances received by him and a record of all such controlled
substances administered, dispensed or professionally used by him
otherwise than by prescription. It shall, however, be sufficient
compliance with this paragraph if any practitioner utilizing controlled
substances listed in Schedules III, IV and V shall keep a record of all
those substances dispensed and distributed by him other than those
controlled substances which are administered by the direct application
of a controlled substance, whether by injection, inhalation, ingestion,
or any other means to the body of a patient or research subject. A
practitioner who dispenses, other than by administering, a controlled
substance in Schedule II, which is a narcotic drug listed in Section
206 of this Act, or which contains any quantity of amphetamine or
methamphetamine, their salts, optical isomers or salts of optical
isomers, pentazocine, or methaqualone, or which is hereafter determined
to be a "designated product" as defined in Section 102 of this Act,
shall do so only upon the issuance of a written prescription blank by a
prescriber; and every practitioner who so dispenses such designated
products shall comply with the provisions of Sections 310 and 311 of
this Act.
(e) Whenever a manufacturer distributes a controlled substance in
a package prepared by him, and whenever a wholesale distributor
distributes a controlled substance in a package prepared by him or the
manufacturer, he shall securely affix to each package in which that
substance is contained a label showing in legible English the name and
address of the manufacturer, the distributor and the quantity, kind and
form of controlled substance contained therein. No person except a
pharmacist and only for the purposes of filling a prescription under
this Act, shall alter, deface or remove any label so affixed.
(f) Whenever a practitioner dispenses any controlled substance, he
[March 24, 2000] 30
shall affix to the container in which such substance is sold or
dispensed, a label indicating the date of initial filling, the
practitioner's name and address, the name of the patient, the name of
the prescriber, the directions for use and cautionary statements, if
any, contained in any prescription or required by law, the proprietary
name or names or the established name of the controlled substance, and
the dosage and quantity, except as otherwise authorized by regulation
by the Department of Professional Regulation. No person shall alter,
deface or remove any label so affixed.
(g) A person to whom or for whose use any controlled substance has
been prescribed or dispensed by a practitioner, or other persons
authorized under this Act, and the owner of any animal for which such
substance has been prescribed or dispensed by a veterinarian, may
lawfully possess such substance only in the container in which it was
delivered to him by the person dispensing such substance.
(h) The responsibility for the proper prescribing or dispensing of
controlled substances is upon the prescriber and the responsibility for
the proper filling of a prescription for controlled substance drugs
rests with the pharmacist. An order purporting to be a prescription
issued to any individual, which is not in the regular course of
professional treatment nor part of an authorized methadone maintenance
program, nor in legitimate and authorized research instituted by any
accredited hospital, educational institution, charitable foundation, or
federal, state or local governmental agency, and which is intended to
provide that individual with controlled substances sufficient to
maintain that individual's or any other individual's physical or
psychological addiction, habitual or customary use, dependence, or
diversion of that controlled substance is not a prescription within the
meaning and intent of this Act; and the person issuing it, shall be
subject to the penalties provided for violations of the law relating to
controlled substances.
(i) A prescriber shall not preprint or cause to be preprinted a
prescription for any controlled substance; nor shall any practitioner
issue, fill or cause to be issued or filled, a preprinted prescription
for any controlled substance.
(j) No person shall manufacture, dispense, deliver, possess with
intent to deliver, prescribe, or administer or cause to be administered
under his direction any anabolic steroid, for any use in humans other
than the treatment of disease in accordance with the order of a
physician licensed to practice medicine in all its branches for a valid
medical purpose in the course of professional practice. The use of
anabolic steroids for the purpose of hormonal manipulation that is
intended to increase muscle mass, strength or weight without a medical
necessity to do so, or for the intended purpose of improving physical
appearance or performance in any form of exercise, sport, or game, is
not a valid medical purpose or in the course of professional practice.
(Source: P.A. 90-253, eff. 7-29-97; 91-576, eff. 4-1-00.)
(720 ILCS 570/313) (from Ch. 56 1/2, par. 1313)
(Text of Section before amendment by P.A. 91-576)
Sec. 313. (a) Controlled substances which are lawfully
administered in hospitals or institutions licensed under the "Hospital
Licensing Act" shall be exempt from the requirements of Sections 308
and 312 except that the prescription for the controlled substance shall
be in writing on the patient's record, signed by the prescriber, dated,
and shall state the name, and quantity of controlled substances ordered
and the quantity actually administered. The records of such
prescriptions shall be maintained for two years and shall be available
for inspection by officers and employees of the Department of State
Police, and the Department of Professional Regulation.
(b) Controlled substances that can lawfully be administered or
dispensed directly to a patient in a long-term care facility licensed
by the Department of Public Health as a skilled nursing facility,
intermediate care facility, or long-term care facility for residents
under 22 years of age, are exempt from the requirements of Sections 308
and 312, except that a prescription for a Schedule II controlled
substance must be either a written prescription signed by the
31 [March 24, 2000]
prescriber or a written prescription transmitted by the prescriber or
prescriber's agent to the dispensing pharmacy by facsimile. The
facsimile serves as the original written prescription and must be
maintained for 2 years from the date of issue in the same manner as a
written prescription signed by the prescriber.
(c) A prescription that is written for a Schedule II controlled
substance to be compounded for direct administration by parenteral,
intravenous, intramuscular, subcutaneous, or intraspinal infusion to a
patient in a private residence, long-term care facility, or hospice
setting may be transmitted by facsimile by the prescriber or the
prescriber's agent to the pharmacy providing the home infusion
services.
(d) Controlled substances which are lawfully administered and/or
dispensed in drug abuse treatment programs licensed by the Department
shall be exempt from the requirements of Sections 308 and 312, except
that the prescription for such controlled substances shall be issued
and authenticated on official prescription logs prepared and supplied
by the Department. The official prescription logs issued by the
Department shall be printed in triplicate on distinctively marked paper
and furnished to programs at reasonable cost. The official
prescription logs furnished to the programs shall contain, in
preprinted form, such information as the Department may require. The
official prescription logs shall be properly endorsed by a physician
licensed to practice medicine in all its branches issuing the order,
with his own signature and the date of ordering, and further endorsed
by the practitioner actually administering or dispensing the dosage at
the time of such administering or dispensing in accordance with
requirements issued by the Department. The duplicate copy shall be
retained by the program for a period of not less than three years nor
more than seven years; the original and triplicate copy shall be
returned to the Department at its principal office in accordance with
requirements set forth by the Department.
(Source: P.A. 89-202, eff. 10-1-95.)
(Text of Section after amendment by P.A. 91-576)
Sec. 313. (a) Controlled substances which are lawfully
administered in hospitals or institutions licensed under the "Hospital
Licensing Act" shall be exempt from the requirements of Sections 312
and 316 except that the prescription for the controlled substance shall
be in writing on the patient's record, signed by the prescriber, dated,
and shall state the name, and quantity of controlled substances ordered
and the quantity actually administered. The records of such
prescriptions shall be maintained for two years and shall be available
for inspection by officers and employees of the Department of State
Police, and the Department of Professional Regulation.
(b) Controlled substances that can lawfully be administered or
dispensed directly to a patient in a long-term care facility licensed
by the Department of Public Health as a skilled nursing facility,
intermediate care facility, or long-term care facility for residents
under 22 years of age, are exempt from the requirements of Section
Sections 312 except that a prescription for a Schedule II controlled
substance must be either a written prescription signed by the
prescriber or a written prescription transmitted by the prescriber or
prescriber's agent to the dispensing pharmacy by facsimile. The
facsimile serves as the original prescription and must be maintained
for 2 years from the date of issue in the same manner as a written
prescription signed by the prescriber and 316.
(c) A prescription that is written for a Schedule II controlled
substance to be compounded for direct administration by parenteral,
intravenous, intramuscular, subcutaneous, or intraspinal infusion to a
patient in a private residence, long-term care facility, or hospice
setting may be transmitted by facsimile by the prescriber or the
prescriber's agent to the pharmacy providing the home infusion
services. The facsimile serves as the original written prescription
for purposes of this paragraph (c) and it shall be maintained in the
same manner as the original written prescription.
(c-1) A prescription written for a Schedule II controlled
[March 24, 2000] 32
substance for a patient residing in a hospice certified by Medicare
under Title XVIII of the Social Security Act or licensed by the State
may be transmitted by the practitioner or the practitioner's agent to
the dispensing pharmacy by facsimile. The practitioner or
practitioner's agent must note on the prescription that the patient is
a hospice patient. The facsimile serves as the original written
prescription for purposes of this paragraph (c-1) and it shall be
maintained in the same manner as the original written prescription.
(Blank).
(d) Controlled substances which are lawfully administered and/or
dispensed in drug abuse treatment programs licensed by the Department
shall be exempt from the requirements of Sections 312 and 316, except
that the prescription for such controlled substances shall be issued
and authenticated on official prescription logs prepared and supplied
by the Department. The official prescription logs issued by the
Department shall be printed in triplicate on distinctively marked paper
and furnished to programs at reasonable cost. The official
prescription logs furnished to the programs shall contain, in
preprinted form, such information as the Department may require. The
official prescription logs shall be properly endorsed by a physician
licensed to practice medicine in all its branches issuing the order,
with his own signature and the date of ordering, and further endorsed
by the practitioner actually administering or dispensing the dosage at
the time of such administering or dispensing in accordance with
requirements issued by the Department. The duplicate copy shall be
retained by the program for a period of not less than three years nor
more than seven years; the original and triplicate copy shall be
returned to the Department at its principal office in accordance with
requirements set forth by the Department.
(Source: P.A. 91-576, eff. 4-1-00.)
(720 ILCS 570/316)
(This Section may contain text from a Public Act with a delayed
effective date)
Sec. 316. Schedule II controlled substance prescription monitoring
program.
The Department must provide for a Schedule II controlled substance
prescription monitoring program that includes the following components:
(1) Each time a Schedule II controlled substance designated by the
Department is dispensed, the dispenser must transmit to the central
repository the following information:
(A) The recipient's name.
(B) The recipient's address.
(C) The national drug code number of the Schedule II
controlled substance dispensed.
(D) The date the Schedule II controlled substance is
dispensed.
(E) The quantity of the Schedule II controlled substance
dispensed.
(F) The dispenser's United States Drug Enforcement Agency
registration number.
(G) The prescriber's United States Drug Enforcement Agency
registration number.
(2) The information required to be transmitted under this Section
must be transmitted not more than 15 days after the date on which a
Schedule II controlled substance is dispensed.
(3) A dispenser must transmit the information required under this
Section by:
(A) an electronic device compatible with the receiving device
of the central repository;
(B) a computer diskette;
(C) a magnetic tape; or
(D) a pharmacy universal claim form or Pharmacy Inventory
Control form;
that meets specifications prescribed by the Department.
Schedule II controlled substance prescription monitoring does not
apply to Schedule II controlled substance prescriptions as exempted
33 [March 24, 2000]
under Section 313. Schedule II controlled substances are exempt from
the requirements of this Section to the extent provided in Section 313.
(Source: P.A. 91-576, eff. 4-1-00.)
Section 95. No acceleration or delay. Where this Act makes
changes in a statute that is represented in this Act by text that is
not yet or no longer in effect (for example, a Section represented by
multiple versions), the use of that text does not accelerate or delay
the taking effect of (i) the changes made by this Act or (ii)
provisions derived from any other Public Act.
Section 99. Effective date. This Act takes effect April 1,
2000.".
AMENDMENT NO. 4. Amend House Bill 2574, AS AMENDED, by replacing
the title with the following:
"AN ACT to amend the Illinois Controlled Substances Act."; and
by replacing the introductory clause of Section 5 with the following:
"Section 5. The Illinois Controlled Substances Act is amended by
changing Sections 102, 201, 204, 206, 208, 210, 214, 309, 312, 313, and
316 and adding Section 217 as follows:"; and
in Section 5, after the last line of Sec. 201, by inserting the
following:
"(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
Sec. 204. (a) The controlled substances listed in this Section are
included in Schedule I.
(b) Unless specifically excepted or unless listed in another
schedule, any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers,
whenever the existence of such isomers, esters, ethers and salts is
possible within the specific chemical designation:
(1) Acetylmethadol;
(1.1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-
4-piperidinyl]-N-phenylacetamide);
(2) Allylprodine;
(3) Alphacetylmethadol, except
levo-alphacetylmethadol (also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM);
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methylfentanyl
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
propanilido) piperidine;
(6.1) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(7) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP);
(7.1) PEPAP
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(8) Benzethidine;
(9) Betacetylmethadol;
(9.1) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-
4-piperidinyl]-N-phenylpropanamide);
(10) Betameprodine;
(11) Betamethadol;
(12) Betaprodine;
(13) Clonitazene;
(14) Dextromoramide;
(15) Diampromide;
(16) Diethylthiambutene;
(17) Difenoxin;
(18) Dimenoxadol;
(19) Dimepheptanol;
(20) Dimethylthiambutene;
(21) Dioxaphetylbutyrate;
[March 24, 2000] 34
(22) Dipipanone;
(23) Ethylmethylthiambutene;
(24) Etonitazene;
(25) Etoxeridine;
(26) Furethidine;
(27) Hydroxpethidine;
(28) Ketobemidone;
(29) Levomoramide;
(30) Levophenacylmorphan;
(31) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-
4-piperidyl]-N-phenylpropanamide);
(31.1) 3-Methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(32) Morpheridine;
(33) Noracymethadol;
(34) Norlevorphanol;
(35) Normethadone;
(36) Norpipanone;
(36.1) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4-piperidinyl]propanamide);
(37) Phenadoxone;
(38) Phenampromide;
(39) Phenomorphan;
(40) Phenoperidine;
(41) Piritramide;
(42) Proheptazine;
(43) Properidine;
(44) Propiram;
(45) Racemoramide;
(45.1) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-
4-piperidinyl]-propanamide);
(46) Tilidine;
(47) Trimeperidine;
(48) Beta-hydroxy-3-methylfentanyl (other name:
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide).
(c) Unless specifically excepted or unless listed in another
schedule, any of the following opium derivatives, its salts, isomers
and salts of isomers, whenever the existence of such salts, isomers and
salts of isomers is possible within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetyldihydromorphine (Dihydroheroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Heroin;
(13) Hydromorphinol;
(14) Methyldesorphine;
(15) Methyldihydromorphine;
(16) Morphine methylbromide;
(17) Morphine methylsulfonate;
(18) Morphine-N-Oxide;
(19) Myrophine;
(20) Nicocodeine;
(21) Nicomorphine;
(22) Normorphine;
35 [March 24, 2000]
(23) Pholcodine;
(24) Thebacon.
(d) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following hallucinogenic substances, or
which contains any of its salts, isomers and salts of isomers, whenever
the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical, position and
geometric isomers):
(1) 3,4-methylenedioxyamphetamine
(alpha-methyl,3,4-methylenedioxyphenethylamine,
methylenedioxyamphetamine, MDA);
(1.1) Alpha-ethyltryptamine
(some trade or other names: etryptamine;
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
3-(2-aminobutyl)indole; a-ET; and AET);
(2) 3,4-methylenedioxymethamphetamine (MDMA);
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
(also known as: N-ethyl-alpha-methyl-
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
and MDEA);
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
(4) 3,4,5-trimethoxyamphetamine (TMA);
(5) (Blank);5-hydroxydimethyltryptamine (Bufotenine);
(6) Diethyltryptamine (DET);
(7) Dimethyltryptamine (DMT);
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
(9) Ibogaine (some trade and other names:
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
indole; Tabernanthe iboga);
(10) Lysergic acid diethylamide;
(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
(12) Peyote (meaning all parts of the plant presently
classified botanically as Lophophora williemaii Lemaire, whether
growing or not, the seeds thereof, any extract from any part of
that plant, and every compound, manufacture, salts, derivative,
mixture, or preparation of that plant, its seeds or extracts);
(13) N-ethyl-3-piperidyl benzilate (JB 318);
(14) N-methyl-3-piperidyl benzilate;
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
(also known as N-hydroxy-alpha-methyl-
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
(15) Parahexyl; some trade or other names:
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo
(b,d) pyran; Synhexyl;
(16) Psilocybin;
(17) Psilocyn;
(18) Alpha-methyltryptamine (AMT);
(19) 2,5-dimethoxyamphetamine
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
(20) 4-bromo-2,5-dimethoxyamphetamine
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4-bromo-2,5-DMA);
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine. Some trade or
other names: 2-(4-bromo- 2,5-dimethoxyphenyl)-1-aminoethane;
alpha-desmethyl DOB, 2CB, Nexus.
(21) 4-methoxyamphetamine
(4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA);
(22) (Blank); Thiophene analog of phencyclidine (TPCP);
(23) Ethylamine analog of phencyclidine. Some trade or other
names: N-ethyl-l-phenylcyclohexylamine, (l-phenylcyclohexyl)
ethylamine, N-(l-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
(24) Pyrrolidine analog of phencyclidine. Some trade or
[March 24, 2000] 36
other names: l-(l-phenylcyclohexyl) pyrrolidine, PCPy, PHP;
(25) 5-methoxy-3,4-methylenedioxy-amphetamine;
(26) 2,5-dimethoxy-4-ethylamphetamine
(another name: DOET);
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
(another name: TCPy);
(28) (Blank);3,4-methylenedioxy amphetamine;
(29) Thiophene analog of phencyclidine (some trade or other
names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog of
phencyclidine; TPCP; TCP);
(30) Bufotenine (some trade or other names:
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)-5-indolol;
5-hydroxy-N,N-dimethyltryptamine;
N,N-dimethylserotonin; mappine).
(e) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a depressant
effect on the central nervous system, including its salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(1) mecloqualone;
(2) methaqualone; and
(3) gamma hydroxybutyric acid.
(f) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a stimulant
effect on the central nervous system, including its salts, isomers, and
salts of isomers:
(1) Fenethylline;
(2) N-ethylamphetamine;
(3) Aminorex (some other names:
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
4-5-dihydro-5-phenyl-2-oxazolamine) and its
salts, optical isomers, and salts of optical isomers;
(4) Methcathinone (some other names:
2-methylamino-1-phenylpropan-1-one;
Ephedrone; 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; N-methylcathinone;
methycathinone; Monomethylpropion; UR 1431) and its
salts, optical isomers, and salts of optical isomers;
(5) Chathinone (some trade or other names:
2-aminopropiophenone; alpha-aminopropiophenone;
2-amino-1-phenyl-propanone; norephedrone);
(6) N,N-dimethylamphetamine (also known as:
N,N-alpha-trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine);
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine).
(g) Temporary listing of substances subject to emergency
scheduling. Any material, compound, mixture, or preparation that
contains any quantity of the following substances:
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
(benzylfentanyl), its optical isomers, isomers, salts, and salts of
isomers;
(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts, and salts of isomers.
(Source: P.A. 89-202, eff. 10-1-95; 90-382, eff. 8-15-97.)
(720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
Sec. 206. (a) The controlled substances listed in this Section are
included in Schedule II.
(b) Unless specifically excepted or unless listed in another
schedule, any of the following substances whether produced directly or
indirectly by extraction from substances of vegetable origin, or
independently by means of chemical synthesis, or by combination of
extraction and chemical synthesis:
37 [March 24, 2000]
(1) Opium and opiates, and any salt, compound, derivative or
preparation of opium or opiate, excluding apomorphine, dextrorphan,
levopropoxyphene, nalbuphine, nalmefene, naloxone, and naltrexone,
and their respective salts, but including the following:
(i) Raw Opium;
(ii) Opium extracts;
(iii) Opium fluid extracts;
(iv) Powdered opium;
(v) Granulated opium;
(vi) Tincture of opium;
(vii) Codeine;
(viii) Ethylmorphine;
(ix) Etorphine Hydrochloride;
(x) Hydrocodone;
(xi) Hydromorphone;
(xii) Metopon;
(xiii) Morphine;
(xiv) Oxycodone;
(xv) Oxymorphone;
(xvi) Thebaine;
(xvii) Thebaine-derived butorphanol.
(2) Any salt, compound, isomer, derivative or preparation
thereof which is chemically equivalent or identical with any of the
substances referred to in subparagraph (1), but not including the
isoquinoline alkaloids of opium;
(3) Opium poppy and poppy straw;
(4) Coca leaves and any salt, compound, isomer, salt of an
isomer, derivative, or preparation of coca leaves including cocaine
or ecgonine, and any salt, compound, isomer, derivative, or
preparation thereof which is chemically equivalent or identical
with any of these substances, but not including decocainized coca
leaves or extractions of coca leaves which do not contain cocaine
or ecgonine (for the purpose of this paragraph, the term "isomer"
includes optical, positional and geometric isomers);
(5) Concentrate of poppy straw (the crude extract of poppy
straw in either liquid, solid or powder form which contains the
phenanthrine alkaloids of the opium poppy).
(c) Unless specifically excepted or unless listed in another
schedule any of the following opiates, including their isomers, esters,
ethers, salts, and salts of isomers, whenever the existence of these
isomers, esters, ethers and salts is possible within the specific
chemical designation, dextrorphan excepted:
(1) Alfentanil;
(1.1) Carfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) Bulk Dextropropoxyphene (non-dosage forms);
(6) Dihydrocodeine;
(7) Diphenoxylate;
(8) Fentanyl;
(9) Sufentanil;
(9.5) Remifentanil;
(10) Isomethadone;
(11) Levomethorphan;
(12) Levorphanol (Levorphan);
(13) Metazocine;
(14) Methadone;
(15) Methadone-Intermediate,
4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
(16) Moramide-Intermediate,
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
acid;
(17) Pethidine (meperidine);
(18) Pethidine-Intermediate-A,
4-cyano-1-methyl-4-phenylpiperidine;
[March 24, 2000] 38
(19) Pethidine-Intermediate-B,
ethyl-4-phenylpiperidine-4-carboxylate;
(20) Pethidine-Intermediate-C,
1-methyl-4-phenylpiperidine-4-carboxylic acid;
(21) Phenazocine;
(22) Piminodine;
(23) Racemethorphan;
(24) Racemorphan;
(25) Levo-alphacetylmethadol (some other names:
levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
(d) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a stimulant
effect on the central nervous system:
(1) Amphetamine, its salts, optical isomers, and salts of its
optical isomers;
(2) Methamphetamine, its salts, isomers, and salts of its
isomers;
(3) Phenmetrazine and its salts;
(4) Methylphenidate.
(e) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a depressant
effect on the central nervous system, including its salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(1) Amobarbital;
(2) Secobarbital;
(3) Pentobarbital;
(4) Pentazocine;
(5) Phencyclidine;
(6) Gluthethimide;
(7) (Blank). Dronabinol (synthetic) in sesame oil and
encapsulated in a soft gelatin capsule in a U.S. Food and Drug
Administration-approved drug product. Some other names:
(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-
pentyl-6H-dibenzo[b,d]pyran-1-ol; (-)-delta-9-(trans)-
tetrahydrocannabinol.
(f) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
(i) Phenylacetone
Some trade or other names: phenyl-2-propanone;
P2P; benzyl methyl ketone; methyl benzyl ketone.
(2) Immediate precursors to phencyclidine:
(i) l-phenylcyclohexylamine;
(ii) l-piperidinocyclohexanecarbonitrile (PCC).
(3) Nabilone.
(Source: P.A. 88-168; 89-202, eff. 10-1-95.)
(720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
Sec. 208. (a) The controlled substances listed in this Section are
included in Schedule III.
(b) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a stimulant
effect on the central nervous system, including its salts, isomers
(whether optical position, or geometric), and salts of such isomers
whenever the existence of such salts, isomers, and salts of isomers is
possible within the specific chemical designation;
(1) Those compounds, mixtures, or preparations in dosage unit
form containing any stimulant substances listed in Schedule II
which compounds, mixtures, or preparations were listed on August
25, 1971, as excepted compounds under Title 21, Code of Federal
Regulations, Section 308.32, and any other drug of the quantitative
composition shown in that list for those drugs or which is the same
39 [March 24, 2000]
except that it contains a lesser quantity of controlled substances;
(2) Benzphetamine;
(3) Chlorphentermine;
(4) Clortermine;
(5) Phendimetrazine.
(c) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a potential
for abuse associated with a depressant effect on the central nervous
system:
(1) Any compound, mixture, or preparation containing
amobarbital, secobarbital, pentobarbital or any salt thereof and
one or more other active medicinal ingredients which are not listed
in any schedule;
(2) Any suppository dosage form containing amobarbital,
secobarbital, pentobarbital or any salt of any of these drugs and
approved by the Federal Food and Drug Administration for marketing
only as a suppository;
(3) Any substance which contains any quantity of a derivative
of barbituric acid, or any salt thereof:
(4) Chlorhexadol;
(5) Methyprylon;
(6) Sulfondiethylmethane;
(7) Sulfonethylmethane;
(8) Sulfonmethane;
(9) Lysergic acid;
(10) Lysergic acid amide;
(10.1) Tiletamine or zolazepam or both, or any salt of either
of them.
Some trade or other names for a tiletamine-zolazepam
combination product: Telazol.
Some trade or other names for Tiletamine:
2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
Some trade or other names for zolazepam:
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
(11) Any material, compound, mixture or preparation
containing not more than 12.5 milligrams of pentazocine or any of
its salts, per 325 milligrams of aspirin;
(12) Any material, compound, mixture or preparation
containing not more than 12.5 milligrams of pentazocine or any of
its salts, per 325 milligrams of acetaminophen;
(13) Any material, compound, mixture or preparation
containing not more than 50 milligrams of pentazocine or any of its
salts plus naloxone HCl USP 0.5 milligrams, per dosage unit;
(14) Ketamine.
(d) Nalorphine.
(e) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation containing
limited quantities of any of the following narcotic drugs, or their
salts calculated as the free anhydrous base or alkaloid, as set forth
below:
(1) not more than 1.8 grams of codeine per 100 milliliters or
not more than 90 milligrams per dosage unit, with an equal or
greater quantity of an isoquinoline alkaloid of opium;
(2) not more than 1.8 grams of codeine per 100 milliliters or
not more than 90 milligrams per dosage unit, with one or more
active non-narcotic ingredients in recognized therapeutic amounts;
(3) not more than 300 milligrams of dihydrocodeinone per 100
milliliters or not more than 15 milligrams per dosage unit, with a
fourfold or greater quantity of an isoquinoline alkaloid of opium;
(4) not more than 300 milligrams of dihydrocodeinone per 100
milliliters or not more than 15 milligrams per dosage unit, with
one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
(5) not more than 1.8 grams of dihydrocodeine per 100
[March 24, 2000] 40
milliliters or not more than 90 milligrams per dosage unit, with
one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
(6) not more than 300 milligrams of ethylmorphine per 100
milliliters or not more than 15 milligrams per dosage unit, with
one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
(7) not more than 500 milligrams of opium per 100 milliliters
or per 100 grams, or not more than 25 milligrams per dosage unit,
with one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
(8) not more than 50 milligrams of morphine per 100
milliliters or per 100 grams with one or more active, non-narcotic
ingredients in recognized therapeutic amounts.
(f) Anabolic steroids, except the following anabolic steroids that
are exempt:
(1) Androgyn L.A.;
(2) Andro-Estro 90-4;
(3) depANDROGYN;
(4) DEPO-T.E.;
(5) depTESTROGEN;
(6) Duomone;
(7) DURATESTRIN;
(8) DUO-SPAN II;
(9) Estratest;
(10) Estratest H.S.;
(11) PAN ESTRA TEST;
(12) Premarin with Methyltestosterone;
(13) TEST-ESTRO Cypionates;
(14) Testosterone Cyp 50 Estradiol Cyp 2;
(15) Testosterone Cypionate-Estradiol Cypionate injection;
and
(16) Testosterone Enanthate-Estradiol Valerate injection.
(g) Hallucenogenic substances.
(1) Dronabinol (synthetic) in sesame oil and encapsulated in
a soft gelatin capsule in a U.S. Food and Drug Administration
approved product. Some other names for dronabinol:
(6aR-trans)-6a,7,8,10a-tetrahydro-
6,6,9-trimetjyl-3-pentyl-6H-debenzo (b,d) pyran-1-ol) or
(-)-delta-9-(trans)-tetrahydrocannibinol.
(2) (Reserved).
(h) The Department may except by rule any compound, mixture, or
preparation containing any stimulant or depressant substance listed in
subsection (b) from the application of all or any part of this Act if
the compound, mixture, or preparation contains one or more active
medicinal ingredients not having a stimulant or depressant effect on
the central nervous system, and if the admixtures are included therein
in combinations, quantity, proportion, or concentration that vitiate
the potential for abuse of the substances which have a stimulant or
depressant effect on the central nervous system.
(Source: P.A. 89-202, eff. 10-1-95; 90-382, eff. 8-15-97.)
(720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
Sec. 210. (a) The controlled substances listed in this Section
are included in Schedule IV.
(b) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation containing
limited quantities of any of the following narcotic drugs, or their
salts calculated as the free anhydrous base or alkaloid, as set forth
below:
(1) Not more than 1 milligram of difenoxin (DEA Drug Code No.
9618) and not less than 25 micrograms of atropine sulfate per
dosage unit.
(2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
2-diphenyl-3-methyl-2-propionoxybutane).
(c) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which
41 [March 24, 2000]
contains any quantity of the following substances having a potential
for abuse associated with a depressant effect on the central nervous
system:
(1) Alprazolam;
(2) Barbital;
(2.1) Bromazepam;
(2.2) Camazepam;
(3) Chloral Betaine;
(4) Chloral Hydrate;
(5) Chlordiazepoxide;
(5.1) Clobazam;
(6) Clonazepam;
(7) Clorazepate;
(7.1) Clotiazepam;
(7.2) Cloxazolam;
(7.3) Delorazepam;
(8) Diazepam;
(8.1) Estazolam;
(9) Ethchlorvynol;
(10) Ethinamate;
(10.1) Ethyl loflazepate;
(10.2) Fludiazepam;
(10.3) Flunitrazepam;
(11) Flurazepam;
(12) Halazepam;
(12.1) Haloxazolam;
(12.2) Ketazolam;
(12.3) Loprazolam;
(13) Lorazepam;
(13.1) Lormetazepam;
(14) Mebutamate;
(14.1) Medazepam;
(15) Meprobamate;
(16) Methohexital;
(17) Methylphenobarbital (Mephobarbital);
(17.1) Midazolam;
(17.2) Nimetazepam;
(17.3) Nitrazepam;
(17.4) Nordiazepam;
(18) Oxazepam;
(18.1) Oxazolam;
(19) Paraldehyde;
(20) Petrichloral;
(21) Phenobarbital;
(21.1) Pinazepam;
(22) Prazepam;
(22.1) Quazepam;
(23) Temazepam;
(23.1) Tetrazepam;
(24) Triazolam;
(24.5) Zaleplon;
(25) Zolpidem Zolpidam.
(d) Any material, compound, mixture, or preparation which contains
any quantity of the following substances, including its salts, isomers
(whether optical, position, or geometric), and salts of such isomers,
whenever the existence of such salts, isomers and salts of isomers is
possible:
(1) Fenfluramine.
(e) Unless specifically excepted or unless listed in another
schedule any material, compound, mixture, or preparation which contains
any quantity of the following substances having a stimulant effect on
the central nervous system, including its salts, isomers (whether
optical, position or geometric), and salts of such isomers whenever the
existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
[March 24, 2000] 42
(1.1) Diethylpropion;
(1.2) Fencamfamin;
(1.3) Fenproporex;
(2) Mazindol;
(2.1) Mefenorex;
(3) Phentermine;
(4) Pemoline (including organometallic complexes and chelates
thereof);
(5) Pipradrol;
(6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);.
(7) Modafinil;
(8) Sibutramine.
(f) Other Substances. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation that contains any quantity of the following substance,
including its salts:
(1) Butorphanol (including its optical isomers).
(g) The Department may except by rule any compound, mixture, or
preparation containing any depressant substance listed in subsection
(b) from the application of all or any part of this Act if the
compound, mixture, or preparation contains one or more active medicinal
ingredients not having a depressant effect on the central nervous
system, and if the admixtures are included therein in combinations,
quantity, proportion, or concentration that vitiate the potential for
abuse of the substances which have a depressant effect on the central
nervous system.
(h) Except as otherwise provided in Section 216, any material,
compound, mixture, or preparation that contains any quantity of the
following substance having a stimulant effect on the central nervous
system, including its salts, enantiomers (optical isomers) and salts of
enantiomers (optical isomers):
(1) Ephedrine, its salts, optical isomers and salts of
optical isomers.
(Source: P.A. 89-202, eff. 10-1-95; 90-775, eff. 1-1-99.)
(720 ILCS 570/214) (from Ch. 56 1/2, par. 1214)
Sec. 214. Excluded Substances.
(a) Products containing an anabolic steroid, that are expressly
intended for administration through implants to cattle or other
nonhuman species and that have been approved by the Secretary of Health
and Human Services for that administration, and that are excluded from
all schedules under Section 102(41)(B)(1) of the federal Controlled
Substances Act (21 U.S.C. 802(41)(B)(1)) are also excluded from
Sections 207 and 208 of this Act.
(b) The non-narcotic substances excluded from all schedules of the
Federal Controlled Substances Act (21 U.S.C. 801 et seq.) pursuant to
Section 1308.22 of the Code of Federal regulations (21 C.F.R. 1308.22),
are excluded from all schedules of this Act.
(Source: P.A. 80-472.)
(720 ILCS 570/217 new)
Sec. 217. Exempt anabolic steroid products. Compounds, mixtures, or
preparations that contain an anabolic steroid that have been exempted
by the Administrator of the federal Drug Enforcement Administration
from application of Sections 302 through 309 and Sections 1002 through
1004 of the federal Controlled Substances Act (21 U.S.C. 822 through
829 and 952 through 954) and 21 CFR 1301.13, 1301.22, and 1301.71
through 1301.76 are also exempt from Sections 207 and 208 of this
Act.".
The foregoing message from the Senate reporting Senate Amendments
numbered 1, 3 and 4 to HOUSE BILL 2574 was placed on the Calendar on
the order of Concurrence.
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House of Representatives in the
43 [March 24, 2000]
passage of a bill of the following title to-wit:
HOUSE BILL 3188
A bill for AN ACT to amend the Township Code by changing Sections
115-20 and 115-105.
Together with the attached amendment thereto (which amendment has
been printed by the Senate), in the adoption of which I am instructed
to ask the concurrence of the House, to-wit:
Senate Amendment No. 1 to HOUSE BILL NO. 3188.
Passed the Senate, as amended, March 24, 2000.
Jim Harry, Secretary of the Senate
AMENDMENT NO. 1. Amend House Bill 3188 on page 2, line 33, by
replacing "5.75%" with "5% 5.75%".
The foregoing message from the Senate reporting Senate Amendment
No. 1 to HOUSE BILL 3188 was placed on the Calendar on the order of
Concurrence.
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House of Representatives in the
passage of a bill of the following title to-wit:
HOUSE BILL 4043
A bill for AN ACT to amend the Liquor Control Act of 1934 by
changing Section 7-5.
Together with the attached amendment thereto (which amendment has
been printed by the Senate), in the adoption of which I am instructed
to ask the concurrence of the House, to-wit:
Senate Amendment No. 1 to HOUSE BILL NO. 4043.
Passed the Senate, as amended, March 24, 2000.
Jim Harry, Secretary of the Senate
AMENDMENT NO. 1. Amend House Bill 4043 on page 1, line 19, by
replacing "$2,000 $1000" with "$1000"; and
on page 1, line 20, by replacing "for each violation; each" with "for a
first each violation within a 12-month period, $1,500 for a second
violation within a 12-month period, and $2,500 for a third or
subsequent violation within a 12-month period. ; Each"; and
on page 1, line 21, by replacing "$20,000" with "$15,000".
The foregoing message from the Senate reporting Senate Amendment
No. 1 to HOUSE BILL 4043 was placed on the Calendar on the order of
Concurrence.
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has concurred with the House of Representatives in the
passage of a bill of the following title to-wit:
[March 24, 2000] 44
HOUSE BILL 4348
A bill for AN ACT in relation to child safety, amending named Acts.
Together with the attached amendment thereto (which amendment has
been printed by the Senate), in the adoption of which I am instructed
to ask the concurrence of the House, to-wit:
Senate Amendment No. 1 to HOUSE BILL NO. 4348.
Passed the Senate, as amended, March 24, 2000.
Jim Harry, Secretary of the Senate
AMENDMENT NO. 1. Amend House Bill 4348 on page 24, by deleting
lines 2 through 32; and
by deleting pages 25 through 36.
The foregoing message from the Senate reporting Senate Amendment
No. 1 to HOUSE BILL 4348 was placed on the Calendar on the order of
Concurrence.
SENATE BILLS ON SECOND READING
Having been printed, the following bills were taken up, read by
title a second time and advanced to the order of Third Reading: SENATE
BILLS 1297, 1326, 1338, 1359, 1397, 1398, 1434, 1474, 1498, 1613, 1617,
1630, 1648, 1650, 1701 and 1861.
SENATE BILL 649. Having been printed, was taken up and read by
title a second time.
The following amendment was offered in the Committee on Judiciary
I-Civil Law, adopted and printed:
AMENDMENT NO. 1 TO SENATE BILL 649
AMENDMENT NO. 1. Amend Senate Bill 649, on page 1, line 8, by
inserting ", human embryo, or human fetus" after "human being"; and
on page 1, line 13, by changing "purchase or sell" to "purchase, sell,
use, or transport"; and
on page 1, by replacing lines 15 and 16 with the following:
"(c) For purposes of this Section, "clone" means to create using
human somatic cell nucleus transfer technology a human being, human
embryo, or human fetus by"; and
on page 1, by replacing lines 19 through 21 with the following:
"removed for any purpose regardless of whether or not the resulting
product could result in a human embryo, human fetus, or human being and
regardless of whether or not it is intended to be implanted into a womb
and may or may not result in a pregnancy and a birth of a human being.
For purposes of this Section, "clone" does not refer to duplicating or
replicating human DNA sequences, organs, tissues, or cells."; and
on page 15, line 3, by changing "for the" to "for any"; and
on page 15, by replacing lines 4 and 5 with the following:
"purpose regardless of whether or not the resulting product could
result in a human embryo, human fetus, or human being, and regardless
of whether or not it is intended to be implanted into a womb and may or
may not result in a pregnancy and a birth of a human being. For the
purposes of this Section, "clone" does not refer to duplicating or
replicating human DNA sequences, organs, tissues, or cells.".
There being no further amendments, the foregoing Amendment No. 1
was adopted and the bill, as amended, was held on the order of Second
Reading.
45 [March 24, 2000]
SENATE BILL 1284. Having been printed, was taken up and read by
title a second time.
The following amendment was offered in the Committee on
Constitutional Officers, adopted and printed:
AMENDMENT NO. 1 TO SENATE BILL 1284
AMENDMENT NO. 1. Amend Senate Bill 1284 by replacing the title
with the following:
"AN ACT in relation to voluntary contributions."; and
by replacing everything after the enacting clause with the following:
"Section 5. The Voluntary Payroll Deductions Act of 1983 is
amended by changing Sections 2, 3, 4, 5, and 8 and adding Section 4.5
as follows:
(5 ILCS 340/2) (from Ch. 15, par. 502)
Sec. 2. Public policy. It is the public policy of this State and
the objective of this Act to lessen the burdens of State government and
of local communities in meeting needs of human health and welfare; to
provide a convenient channel through which State employees and State
annuitants public servants may contribute to these efforts; to minimize
or eliminate disruption of the State workplace and costs to State
taxpayers that such fund-raising may entail; to serve needs of human
health and welfare; and to ensure that recipient organizations are
responsible in the uses of the moneys so raised.
(Source: P.A. 90-487, eff. 8-17-97.)
(5 ILCS 340/3) (from Ch. 15, par. 503)
Sec. 3. Definitions. As used in this Act unless the context
otherwise requires:
(a) "Employee" means any regular officer or employee who receives
salary or wages for personal services rendered to the State of
Illinois, and includes an individual hired as an employee by contract
with that individual.
(b) "Qualified organization" means an organization representing
one or more benefiting agencies, which organization is designated by
the State Comptroller as qualified to receive payroll deductions under
this Act. An organization desiring to be designated as a qualified
organization shall:
(1) Submit written designations on forms approved by the
State Comptroller by 4,000 or more employees or State annuitants,
in which such employees or State annuitants indicate that the
organization is one for which the employee or State annuitant
intends to authorize withholding. The forms shall require the
name, social security number, and employing State agency for each
employee. Upon notification by the Comptroller that such forms
have been approved, the organization shall, within 30 days, notify
in writing the Governor or his or her designee of its intention to
obtain the required number of designations. Such organization
shall have 12 months from that date, to obtain the necessary
designations. The signed forms and signatures on the forms shall
be subject to verification by the State Comptroller;
(2) Certify that all benefiting agencies are tax exempt under
Section 501(c)(3) of the Internal Revenue Code;
(3) Certify that all benefiting agencies are in compliance
with the Illinois Human Rights Act;
(4) Certify that all benefiting agencies are in compliance
with the Charitable Trust Act and the Solicitation for Charity Act;
(5) Certify that all benefiting agencies actively conduct
health or welfare programs and provide services to individuals
directed at one or more of the following common human needs within
a community: service, research, and education in the health fields;
family and child care services; protective services for children
and adults; services for children and adults in foster care;
services related to the management and maintenance of the home; day
care services for adults; transportation services; information,
referral and counseling services; services to eliminate illiteracy;
the preparation and delivery of meals; adoption services; emergency
[March 24, 2000] 46
shelter care and relief services; disaster relief services; safety
services; neighborhood and community organization services;
recreation services; social adjustment and rehabilitation services;
health support services; or a combination of such services designed
to meet the special needs of specific groups, such as children and
youth, the ill and infirm, and the physically handicapped; and that
all such benefiting agencies provide the above described services
to individuals and their families in the community and surrounding
area in which the organization conducts its fund drive, or that
such benefiting agencies provide relief to victims of natural
disasters and other emergencies on a where and as needed basis;
(6) Certify that the organization has disclosed the
percentage of the organization's total collected receipts from
employees or State annuitants that are distributed to the
benefiting agencies and the percentage of the organization's total
collected receipts from employees or State annuitants that are
expended for fund-raising and overhead costs. These percentages
shall be the same percentage figures annually disclosed by the
organization to the Attorney General. The disclosure shall be made
to all solicited employees and State annuitants and shall be in the
form of a factual statement on all petitions and in the campaign's
brochures for employees and State annuitants employee brochure;
(7) Certify that all benefiting agencies receiving funds
which the employee or State annuitant has requested or designated
for distribution to a particular community and surrounding area use
a majority of such funds distributed for services in the actual
provision of services in that community and surrounding area;
(8) Certify that neither it nor its member organizations will
solicit State employees for contributions at their workplace,
except pursuant to this Act and the rules promulgated thereunder.
Each qualified organization, and each participating United Fund, is
encouraged to cooperate with all others and with all State agencies
and educational institutions so as to simplify procedures, to
resolve differences and to minimize costs;
(9) Certify that it will pay its share of the campaign costs
and will comply with the Code of Campaign Conduct as approved by
the Governor or other agency as designated by the Governor; and
(10) Certify that it maintains a year-round office, the
telephone number, and person responsible for the operations of the
organization in Illinois. That information shall be provided to
the State Comptroller at the time the organization is seeking
participation under this Act.
Each qualified organization shall submit to the State Comptroller
between January 1 and March 1 of each year, a statement that the
organization is in compliance with all of the requirements set forth in
paragraphs (2) through (10). The State Comptroller shall exclude any
organization that fails to submit the statement from the next
solicitation period.
In order to be designated as a qualified organization, the
organization shall have existed at least 2 years prior to submitting
the written designation forms required in paragraph (1) and shall
certify to the State Comptroller that such organization has been
providing services described in paragraph (5) in Illinois. If the
organization seeking designation represents more than one benefiting
agency, it need not have existed for 2 years but shall certify to the
State Comptroller that each of its benefiting agencies has existed for
at least 2 years prior to submitting the written designation forms
required in paragraph (1) and that each has been providing services
described in paragraph (5) in Illinois.
Organizations which have met the requirements of this Act shall be
permitted to participate in the State and Universities Combined Appeal
as of January 1st of the year immediately following their approval by
the Comptroller.
Where the certifications described in paragraphs (2), (3), (4),
(5), (6), (7), (8), (9), and (10) above are made by an organization
representing more than one benefiting agency they shall be based upon
47 [March 24, 2000]
the knowledge and belief of such qualified organization. Any qualified
organization shall immediately notify the State Comptroller in writing
if the qualified organization receives information or otherwise
believes that a benefiting agency is no longer in compliance with the
certification of the qualified organization. A qualified organization
representing more than one benefiting agency shall thereafter withhold
and refrain from distributing to such benefiting agency those funds
received pursuant to this Act until the benefiting agency is again in
compliance with the qualified organization's certification. The
qualified organization shall immediately notify the State Comptroller
of the benefiting agency's resumed compliance with the certification,
based upon the qualified organization's knowledge and belief, and shall
pay over to the benefiting agency those funds previously withheld.
The Comptroller shall, by February 1st of each year, so notify any
qualified organization that failed to receive at least 500 payroll
deduction pledges during each immediately preceding solicitation period
as set forth in Section 6. The notification shall give such qualified
organization until March 1st to provide the Comptroller with
documentation that the 500 deduction requirement has been met. On the
basis of all the documentation, the Comptroller shall, by March 15th of
each year, submit to the Governor or his or her designee, or such other
agency as may be determined by the Governor, a list of all
organizations which have met the 500 payroll deduction requirement.
Only those organizations which have met such requirements, as well as
the other requirements of this Section, shall be permitted to solicit
State employees or State annuitants for voluntary contributions, and
the Comptroller shall discontinue withholding for any such organization
which fails to meet these requirements.
(c) "United Fund" means the organization conducting the single,
annual, consolidated effort to secure funds for distribution to
agencies engaged in charitable and public health, welfare and services
purposes, which is commonly known as the United Fund, or the
organization which serves in place of the United Fund organization in
communities where an organization known as the United Fund is not
organized.
In order for a United Fund to participate in the State and
Universities Employees Combined Appeal, it shall comply with the
provisions of paragraph (9) of subsection (b).
(d) "State and Universities Employees Combined Appeal" (SECA),
otherwise known as "SECA", means the State-directed joint effort of all
of the qualified organizations, together with the United Funds, for the
solicitation of voluntary contributions from State and University
employees and State annuitants.
(e) "Retirement system" means any or all of the following: the
General Assembly Retirement System, the State Employees' Retirement
System of Illinois, the State Universities Retirement System, the
Teachers' Retirement System of the State of Illinois, and the Judges
Retirement System.
(f) "State annuitant" means a person receiving an annuity or
disability benefit under Article 2, 14, 15, 16, or 18 of the Illinois
Pension Code.
(Source: P.A. 90-487, eff. 8-17-97; 91-357, eff. 7-29-99; 91-533, eff.
8-13-99.)
(5 ILCS 340/4) (from Ch. 15, par. 504)
Sec. 4. Employee withholding. An employee may authorize the
withholding of a portion of his or her salary or wages for contribution
to a maximum number of 4 organizations described in paragraphs (b) and
(c) of Section 3 of this Act. A department, board, body, agency or
commission may direct the State Comptroller to deduct, and the
University of Illinois, Southern Illinois University, Chicago State
University, Eastern Illinois University, Governors State University,
Illinois State University, Northeastern Illinois University, Northern
Illinois University, and Western Illinois University may deduct, upon
written request of a State employee, for each regular payroll period,
from the salary or wages of the employee the amount specified in the
written request for payment to the organization designated by the
[March 24, 2000] 48
employee. The moneys so deducted shall be paid over promptly to the
organizations designated by the employee by means of warrants drawn by
the State Comptroller, the University of Illinois, Southern Illinois
University, Chicago State University, Eastern Illinois University,
Governors State University, Illinois State University, Northeastern
Illinois University, Northern Illinois University, and Western Illinois
University, against the appropriation for personal services of the
department, board, body, agency or commission by which such employee is
employed.
Such deductions may be made notwithstanding that the compensation
paid in cash to such employee is thereby reduced below the minimum
prescribed by law. Payment to such employee of compensation less such
deduction shall constitute a full and complete discharge and
acquittance of all claims and demands whatsoever for the services
rendered by such employee during the period covered by such payment.
Such request for deduction may be withdrawn at any time by filing a
written notification of withdrawal with the department, board, body,
agency or commission, the University of Illinois, Southern Illinois
University, Chicago State University, Eastern Illinois University,
Governors State University, Illinois State University, Northeastern
Illinois University, Northern Illinois University, or Western Illinois
University, by which such employee is employed.
(Source: P.A. 89-4, eff. 1-1-96.)
(5 ILCS 340/4.5 new)
Sec. 4.5. State annuitant withholding. A State annuitant may
authorize the withholding of a portion of his or her annuity or
disability benefit for contribution to a maximum of 4 organizations
described in paragraphs (b) and (c) of Section 3 of this Act. Upon
written request of a State annuitant, a retirement system may deduct or
direct the State Comptroller to deduct from the annuity or disability
benefit of the State annuitant the amount specified in the written
request for payment to the organization designated by the State
annuitant. The retirement system may determine the timing for the
deductions based on the retirement system's benefit processing
schedule. The moneys so deducted shall be paid over promptly to the
organizations designated by the State annuitant by means of warrants
drawn by the retirement system or the State Comptroller against the
fund from which the State annuitant is receiving his or her annuity or
disability benefit.
Withholding under this Section may be terminated by the State
annuitant at any time by filing a written direction with the retirement
system.
Each retirement system may promulgate rules regarding the
administration of this Section with respect to persons receiving an
annuity or disability benefit from the retirement system.
(5 ILCS 340/5) (from Ch. 15, par. 505)
Sec. 5. Rules; Advisory Committee. The State Comptroller shall
promulgate and issue reasonable rules and regulations as deemed
necessary for the administration of this Act.
However, all solicitations of State employees for contributions at
their workplace and all solicitations of State annuitants for
contributions shall be in accordance with rules promulgated by the
Governor or his or her designee or other agency as may be designated by
the Governor. All solicitations of State annuitants for contributions
shall also be in accordance with the rules promulgated by the
applicable retirement system.
The rules promulgated by the Governor or his or her designee or
other agency as designated by the Governor shall include a Code of
Campaign Conduct that all qualified organizations and United Funds
shall subscribe to in writing, sanctions for violations of the Code of
Campaign Conduct, provision for the handling of cash contributions,
provision for an Advisory Committee, provisions for the allocation of
expenses among the participating organizations, an organizational plan
and structure whereby responsibilities are set forth for the
appropriate State employees or State annuitants and the participating
organizations, and any other matters that are necessary to accomplish
49 [March 24, 2000]
the purposes of this Act.
The Governor or the Governor's designee shall promulgate rules to
establish the composition and the duties of the Advisory Committee.
The Governor or the Governor's designee shall make appointments to the
Advisory Committee. The powers of the Advisory Committee shall
include, at a minimum, the ability to impose the sanctions authorized
by rule. Each State agency and each retirement system shall file an
annual report that sets forth, for the prior calendar year, (i) the
total amount of money contributed to each qualified organization and
united fund through both payroll deductions and cash contributions,
(ii) the number of employees or State annuitants who have contributed
to each qualified organization and united fund, and (iii) any other
information required by the rules. The report shall not include the
names of any contributing or non-contributing employees or State
annuitants employee. The report shall be filed with the Advisory
Committee no later than March 15 of each year for the solicitation
period immediately preceding the report. The report shall be available
for inspection.
Other constitutional officers, retirement systems, the University
of Illinois, Southern Illinois University, Chicago State University,
Eastern Illinois University, Governors State University, Illinois State
University, Northeastern Illinois University, Northern Illinois
University, and Western Illinois University shall be governed by the
rules promulgated pursuant to this Section, unless such entities adopt
their own rules governing solicitation of contributions at the
workplace.
All rules promulgated pursuant to this Section shall not
discriminate against one or more qualified organizations or United
Funds.
(Source: P.A. 89-4, eff. 1-1-96; 90-799, eff. 6-1-99.)
(5 ILCS 340/8)
Sec. 8. Reports.
(a) The Comptroller shall annually prepare a report on the number
of State and university employees and State annuitants who have
contributed to qualified organizations and united funds under this Act
during the prior calendar year. The report shall set forth (i) the
number of payroll deductions received by each qualified organization
and united fund, (ii) the total amount of the contributions received by
each qualified organization and united fund, and (iii) the State
agencies, and universities, and retirement systems from which the
contributions were received. The report shall be prepared no later
than April 1 of each year and shall be available to the public upon
request.
(b) By March 1 of each year, each university shall submit to the
Comptroller a report containing the information required for the
preparation of the Comptroller's report under subsection (a) with
respect to that university and its employees.
(c) By March 1 of each year, each retirement system shall submit
to the Comptroller a report containing the information required for the
preparation of the Comptroller's report under subsection (a) with
respect to that retirement system and its participating State
annuitants. The Comptroller may waive this reporting requirement for
any retirement system if the Comptroller performs the retirement
processing for the retirement system.
(Source: P.A. 90-799, eff. 6-1-99.)
Section 99. Effective date. This Act takes effect upon becoming
law.".
There being no further amendments, the foregoing Amendment No. 1
was adopted and the bill, as amended, was advanced to the order of
Third Reading.
ACTION ON MOTIONS
Representative Cross moved suspend the provison of Rule 18(g) and
[March 24, 2000] 50
discharge the Committee on Rules from further consideration of HOUSE
BILL 2963 and that it be advanced to the order of Second Reading.
Representative Murphy objected to that motion.
Representative Black moved that a record vote be taken on the
motion to discharge HOUSE BILL 2963.
The Chair ruled the request out of order.
Representative Black moved to overrule the Chair.
And the question being "Shall the Chair be sustained?" it was
decided in the affirmative by the following vote:
60, Yeas; 53, Nays; 0, Answering Present.
(ROLL CALL 2)
The motion prevailed.
SENATE BILLS ON SECOND READING
SENATE BILL 1550. Having been printed, was taken up and read by
title a second time.
The following amendments were offered in the Committee on
Executive, adopted and printed:
AMENDMENT NO. 1 TO SENATE BILL 1550
AMENDMENT NO. 1. Amend Senate Bill 1550 on page 1, by replacing
lines 1 and 2 with the following:
"AN ACT in relation to alcoholic liquor, amending named Acts."; and
on page 1, by inserting the following after line 4:
"Section 3. The Alcoholism and Other Drug Abuse and Dependency Act
is amended by changing Section 15-10 as follows:
(20 ILCS 301/15-10)
Sec. 15-10. Licensure categories. No person or program may
provide the services or conduct the activities described in this
Section without first obtaining a license therefor from the Department.
The Department shall, by rule, provide licensure requirements for each
of the following categories of service:
(a) residential treatment for alcoholism and other drug abuse
and dependency.
(b) outpatient treatment for alcoholism and other drug abuse
and dependency.
(c) the screening, assessment, referral or tracking of
clients identified by the criminal justice system as having
indications of alcoholism or other drug abuse or dependency.
(d) D.U.I. evaluation services for Illinois courts and the
Secretary of State.
(e) D.U.I. remedial education services for Illinois courts or
the Secretary of State.
(f) persons providing education and training to beverage
alcohol servers and sellers, as defined by the Department.
The Department may, under procedures established by rule and upon a
showing of good cause for such, exempt off-site services from having to
obtain a separate license for services conducted away from the
provider's primary service location.
(Source: P.A. 88-80.)"; and
on page 1, line 6, by replacing "Section 6-15" with "Sections 3-12,
6-15, and 6-27"; and
on page 1, by inserting the following after line 6:
"(235 ILCS 5/3-12) (from Ch. 43, par. 108)
Sec. 3-12. Powers and duties of State Commission.
(a) The State commission shall have the following powers,
functions and duties:
(1) To receive applications and to issue licenses to
manufacturers, foreign importers, importing distributors, distributors,
non-resident dealers, on premise consumption retailers, off premise
sale retailers, special event retailer licensees, special use permit
licenses, auction liquor licenses, brew pubs, caterer retailers,
non-beverage users, railroads, including owners and lessees of
51 [March 24, 2000]
sleeping, dining and cafe cars, airplanes, boats, brokers, and wine
maker's retail licensees in accordance with the provisions of this Act,
and to suspend or revoke such licenses upon the State commission's
determination, upon notice after hearing, that a licensee has violated
any provision of this Act or any rule or regulation issued pursuant
thereto and in effect for 30 days prior to such violation.
In lieu of suspending or revoking a license, the commission may
impose a fine, upon the State commission's determination and notice
after hearing, that a licensee has violated any provision of this Act
or any rule or regulation issued pursuant thereto and in effect for 30
days prior to such violation. The fine imposed under this paragraph
may not exceed $500 for each violation. Each day that the activity,
which gave rise to the original fine, continues is a separate
violation. The maximum fine that may be levied against any licensee,
for the period of the license, shall not exceed $20,000. The maximum
penalty that may be imposed on a licensee for selling a bottle of
alcoholic liquor with a foreign object in it or serving from a bottle
of alcoholic liquor with a foreign object in it shall be the
destruction of that bottle of alcoholic liquor for the first 10 bottles
so sold or served from by the licensee. For the eleventh bottle of
alcoholic liquor and for each third bottle thereafter sold or served
from by the licensee with a foreign object in it, the maximum penalty
that may be imposed on the licensee is the destruction of the bottle of
alcoholic liquor and a fine of up to $50.
(2) To adopt such rules and regulations consistent with the
provisions of this Act which shall be necessary to carry on its
functions and duties to the end that the health, safety and welfare of
the People of the State of Illinois shall be protected and temperance
in the consumption of alcoholic liquors shall be fostered and promoted
and to distribute copies of such rules and regulations to all licensees
affected thereby.
(3) To call upon other administrative departments of the State,
county and municipal governments, county and city police departments
and upon prosecuting officers for such information and assistance as it
deems necessary in the performance of its duties.
(4) To recommend to local commissioners rules and regulations, not
inconsistent with the law, for the distribution and sale of alcoholic
liquors throughout the State.
(5) To inspect, or cause to be inspected, any premises in this
State where alcoholic liquors are manufactured, distributed,
warehoused, or sold.
(5.1) Upon receipt of a complaint or upon having knowledge that
any person is engaged in business as a manufacturer, importing
distributor, distributor, or retailer without a license or valid
license, to notify the local liquor authority, file a complaint with
the State's Attorney's Office of the county where the incident
occurred, or initiate an investigation with the appropriate law
enforcement officials.
(5.2) To issue a cease and desist notice to persons shipping
alcoholic liquor into this State from a point outside of this State if
the shipment is in violation of this Act.
(5.3) To receive complaints from licensees, local officials, law
enforcement agencies, organizations, and persons stating that any
licensee has been or is violating any provision of this Act or the
rules and regulations issued pursuant to this Act. Such complaints
shall be in writing, signed and sworn to by the person making the
complaint, and shall state with specificity the facts in relation to
the alleged violation. If the Commission has reasonable grounds to
believe that the complaint substantially alleges a violation of this
Act or rules and regulations adopted pursuant to this Act, it shall
conduct an investigation. If, after conducting an investigation, the
Commission is satisfied that the alleged violation did occur, it shall
proceed with disciplinary action against the licensee as provided in
this Act.
(6) To hear and determine appeals from orders of a local
commission in accordance with the provisions of this Act, as
[March 24, 2000] 52
hereinafter set forth. Hearings under this subsection shall be held in
Springfield or Chicago, at whichever location is the more convenient
for the majority of persons who are parties to the hearing.
(7) The commission shall establish uniform systems of accounts to
be kept by all retail licensees having more than 4 employees, and for
this purpose the commission may classify all retail licensees having
more than 4 employees and establish a uniform system of accounts for
each class and prescribe the manner in which such accounts shall be
kept. The commission may also prescribe the forms of accounts to be
kept by all retail licensees having more than 4 employees, including
but not limited to accounts of earnings and expenses and any
distribution, payment, or other distribution of earnings or assets, and
any other forms, records and memoranda which in the judgment of the
commission may be necessary or appropriate to carry out any of the
provisions of this Act, including but not limited to such forms,
records and memoranda as will readily and accurately disclose at all
times the beneficial ownership of such retail licensed business. The
accounts, forms, records and memoranda shall be available at all
reasonable times for inspection by authorized representatives of the
State commission or by any local liquor control commissioner or his or
her authorized representative. The commission, may, from time to time,
alter, amend or repeal, in whole or in part, any uniform system of
accounts, or the form and manner of keeping accounts.
(8) In the conduct of any hearing authorized to be held by the
commission, to examine, or cause to be examined, under oath, any
licensee, and to examine or cause to be examined the books and records
of such licensee; to hear testimony and take proof material for its
information in the discharge of its duties hereunder; to administer or
cause to be administered oaths; and for any such purpose to issue
subpoena or subpoenas to require the attendance of witnesses and the
production of books, which shall be effective in any part of this
State.
Any Circuit Court may by order duly entered, require the attendance
of witnesses and the production of relevant books subpoenaed by the
State commission and the court may compel obedience to its order by
proceedings for contempt.
(9) To investigate the administration of laws in relation to
alcoholic liquors in this and other states and any foreign countries,
and to recommend from time to time to the Governor and through him or
her to the legislature of this State, such amendments to this Act, if
any, as it may think desirable and as will serve to further the general
broad purposes contained in Section 1-2 hereof.
(10) To adopt such rules and regulations consistent with the
provisions of this Act which shall be necessary for the control, sale
or disposition of alcoholic liquor damaged as a result of an accident,
wreck, flood, fire or other similar occurrence.
(11) To develop industry educational programs related to
responsible serving and selling, particularly in the areas of
overserving consumers and illegal underage purchasing and consumption
of alcoholic beverages.
(11.1) To license persons providing education and training to
alcohol beverage sellers and servers under the Beverage Alcohol Sellers
and Servers Education and Training (BASSET) programs and to develop and
administer a public awareness program in Illinois to reduce or
eliminate the illegal purchase and consumption of alcoholic beverage
products by persons under the age of 21. Application for a license
shall be made on forms provided by the State Commission.
(12) To develop and maintain a repository of license and
regulatory information.
(13) On or before January 15, 1994, the Commission shall issue a
written report to the Governor and General Assembly that is to be based
on a comprehensive study of the impact on and implications for the
State of Illinois of Section 1926 of the Federal ADAMHA Reorganization
Act of 1992 (Public Law 102-321). This study shall address the extent
to which Illinois currently complies with the provisions of P.L.
102-321 and the rules promulgated pursuant thereto.
53 [March 24, 2000]
As part of its report, the Commission shall provide the following
essential information:
(i) the number of retail distributors of tobacco products, by
type and geographic area, in the State;
(ii) the number of reported citations and successful
convictions, categorized by type and location of retail
distributor, for violation of the Sale of Tobacco to Minors Act and
the Smokeless Tobacco Limitation Act;
(iii) the extent and nature of organized educational and
governmental activities that are intended to promote, encourage or
otherwise secure compliance with any Illinois laws that prohibit
the sale or distribution of tobacco products to minors; and
(iv) the level of access and availability of tobacco products
to individuals under the age of 18.
To obtain the data necessary to comply with the provisions of P.L.
102-321 and the requirements of this report, the Commission shall
conduct random, unannounced inspections of a geographically and
scientifically representative sample of the State's retail tobacco
distributors.
The Commission shall consult with the Department of Public Health,
the Department of Human Services, the Illinois State Police and any
other executive branch agency, and private organizations that may have
information relevant to this report.
The Commission may contract with the Food and Drug Administration
of the U.S. Department of Health and Human Services to conduct
unannounced investigations of Illinois tobacco vendors to determine
compliance with federal laws relating to the illegal sale of cigarettes
and smokeless tobacco products to persons under the age of 18.
(b) On or before April 30, 1999, the Commission shall present a
written report to the Governor and the General Assembly that shall be
based on a study of the impact of this amendatory Act of 1998 on the
business of soliciting, selling, and shipping alcoholic liquor from
outside of this State directly to residents of this State.
As part of its report, the Commission shall provide the following
information:
(i) the amount of State excise and sales tax revenues
generated as a result of this amendatory Act of 1998;
(ii) the amount of licensing fees received as a result of
this amendatory Act of 1998;
(iii) the number of reported violations, the number of cease
and desist notices issued by the Commission, the number of notices
of violations issued to the Department of Revenue, and the number
of notices and complaints of violations to law enforcement
officials.
(Source: P.A. 90-9, eff. 7-1-97; 90-432, eff. 1-1-98; 90-655, eff.
7-30-98; 90-739, eff. 8-13-98; 91-553, eff. 8-14-99.)"; and
on page 13, by inserting the following after line 22:
"(235 ILCS 5/6-27) (from Ch. 43, par. 144c)
Sec. 6-27. Licensing of seller and server education programs.
(a) Any program designed to educate or train employees who sell or
serve alcoholic beverages at retail to identify and address persons
displaying problems with alcohol misuse or abuse shall be licensed by
the State Commission Department of Human Services.
(b) A seller and server education program license in effect on the
effective date of this amendatory Act of the 91st General Assembly
shall remain in effect until June 30, 2000.
(Source: P.A. 89-507, eff. 7-1-97.)
Section 99. Effective date. This Act takes effect upon becoming
law.".
AMENDMENT NO. 2 TO SENATE BILL 1550
AMENDMENT NO. 2. Amend Senate Bill 1550 on page 1, by replacing
lines 1 and 2 with the following:
"AN ACT to amend the Liquor Control Act of 1934 by changing
Sections 6-15 and 7-8."; and
[March 24, 2000] 54
on page 1, by replacing lines 5 and 6 with the following:
"Section 5. The Liquor Control Act of 1934 is amended by changing
Sections 6-15 and 7-8 as follows:"; and
on page 13, after line 22, by inserting the following:
"(235 ILCS 5/7-8) (from Ch. 43, par. 152)
Sec. 7-8. For each city, village or incorporated town having a
population of 500,000 or more inhabitants, there is established a
license appeal commission consisting of the chairman of the Illinois
Liquor Control Commission, the most senior member of the Illinois
Liquor Control Commission who is not of the same political party as the
chairman, and one person who is a resident of the particular city,
village or incorporated town selected by the council or president and
board of trustees, as the case may be, who shall serve for a term of 4
years and until his successor is selected and takes office. Neither the
mayor, president of the board of trustees, nor any member of the
council or board of trustees shall be eligible for membership on a
license appeal commission. Each of the 2 members of the Illinois Liquor
Control Commission shall receive a $200 $100 per diem for their work on
the license appeal commission, and the other member shall receive an
annual salary which shall be paid by the particular city, village or
incorporated town. The secretary of the Illinois Liquor Control
Commission shall be ex-officio the secretary for each license appeal
commission.
(Source: P.A. 84-1282.)".
There being no further amendments, the foregoing Amendments
numbered 1 and 2 were adopted and the bill, as amended, was advanced to
the order of Third Reading.
SENATE BILL 1682. Having been printed, was taken up and read by
title a second time.
The following amendment was offered in the Committee on Executive,
adopted and printed:
AMENDMENT NO. 1 TO SENATE BILL 1682
AMENDMENT NO. 1. Amend Senate Bill 1682 by deleting lines 11
through 30 on page 4 and lines 1 through 32 on page 5.
There being no further amendments, the foregoing Amendment No. 1
was adopted and the bill, as amended, was advanced to the order of
Third Reading.
SENATE BILL 1690. Having been printed, was taken up and read by
title a second time.
The following amendment was offered in the Committee on Judiciary
I-Civil Law, adopted and printed:
AMENDMENT NO. 1 TO SENATE BILL 1690
AMENDMENT NO. 1. Amend Senate Bill 1690 as follows:
on page 1, lines 2 and 6, by replacing "Sections 6 and" each time it
appears with "Section"; and
by deleting lines 7 through 31; and
by deleting all of page 2; and
on page 3, by deleting lines 1 through 13; and
on line 26, by replacing "paragraph (7)" with "paragraphs paragraph (7)
and (8)".
There being no further amendments, the foregoing Amendment No. 1
was adopted and the bill, as amended, was advanced to the order of
Third Reading.
RESOLUTIONS
55 [March 24, 2000]
HOUSE RESOLUTIONS 656, 657, 658, 659, 660, 663, 664, 665, 666, 667,
668, 670, 672, 673, 674, 675, 676 and 692 were taken up for
consideration.
MESSAGES FROM THE SENATE
A message from the Senate by
Mr. Harry, Secretary:
Mr. Speaker -- I am directed to inform the House of Representatives
that the Senate has adopted the following Senate Joint Resolution, in
the adoption of which I am instructed to ask the concurrence of the
House of Representatives, to-wit:
SENATE JOINT RESOLUTION NO. 65
RESOLVED, BY THE SENATE OF THE NINETY-FIRST GENERAL ASSEMBLY OF THE
STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES CONCURRING HEREIN, that
when the two Houses adjourn on Friday, March 24, 2000, the Senate
stands adjourned until Tuesday, March 28, 2000, at 12:00 o'clock noon;
and the House of Representatives stands adjourned until Tuesday, March
28, 2000, at 1:00 o'clock p.m.
Adopted by the Senate, March 24, 2000.
Jim Harry, Secretary of the Senate
The foregoing message from the Senate reporting their adoption of
Senate Joint Resolution 65 was taken up for immediate consideration.
Representative Currie moved the adoption of the resolution.
The motion prevailed and SENATE JOINT RESOLUTION 65 was adopted.
Ordered that the Clerk inform the Senate.
At the hour of 2:50 o'clock p.m., Representative Currie moved that
the House do now adjourn.
The motion prevailed.
And in accordance therewith and pursuant to SENATE JOINT RESOLUTION
65, the House stood adjourned until Tuesday, March 28, 2000, at 1:00
o'clock p.m.
[March 24, 2000] 56
NO. 1
STATE OF ILLINOIS
NINETY-FIRST
GENERAL ASSEMBLY
HOUSE ROLL CALL
QUORUM ROLL CALL FOR ATTENDANCE
MAR 24, 2000
0 YEAS 0 NAYS 113 PRESENT
P ACEVEDO P FOWLER E LINDNER P REITZ
P BASSI P FRANKS P LOPEZ P RIGHTER
P BEAUBIEN P FRITCHEY P LYONS,EILEEN P RUTHERFORD
P BELLOCK P GARRETT P LYONS,JOSEPH P RYDER
P BIGGINS P GASH P MATHIAS P SAVIANO
P BLACK E GIGLIO P MAUTINO P SCHMITZ
P BOLAND P GILES P McAULIFFE P SCHOENBERG
P BOST P GRANBERG P McCARTHY P SCOTT
P BRADLEY P HAMOS P McGUIRE P SCULLY
P BRADY P HANNIG P McKEON P SHARP
P BROSNAHAN P HARRIS P MEYER P SILVA
P BRUNSVOLD P HARTKE P MITCHELL,BILL P SKINNER
P BUGIELSKI P HASSERT P MITCHELL,JERRY P SLONE
P BURKE P HOEFT P MOFFITT P SMITH
P CAPPARELLI P HOFFMAN P MOORE P SOMMER
P COULSON P HOLBROOK P MORROW P STEPHENS
P COWLISHAW P HOWARD P MULLIGAN P STROGER
P CROSS P HULTGREN P MURPHY P TENHOUSE
P CROTTY P JOHNSON,TIM P MYERS P TURNER,ART
P CURRIE P JOHNSON,TOM P NOVAK P TURNER,JOHN
P CURRY P JONES,JOHN P O'BRIEN P WAIT
P DANIELS P JONES,LOU P O'CONNOR P WINKEL
P DART P JONES,SHIRLEY P OSMOND P WINTERS
P DAVIS,MONIQUE P KENNER P OSTERMAN P WIRSING
P DAVIS,STEVE P KLINGLER P PANKAU P WOJCIK
P DELGADO P KOSEL P PARKE P WOOLARD
P DURKIN P KRAUSE E PERSICO P YOUNGE
E ERWIN P LANG P POE E ZICKUS
P FEIGENHOLTZ P LAWFER P PUGH P MR. SPEAKER
P FLOWERS P LEITCH
E - Denotes Excused Absence
57 [March 24, 2000]
NO. 2
STATE OF ILLINOIS
NINETY-FIRST
GENERAL ASSEMBLY
HOUSE ROLL CALL
HOUSE BILL 2963
MOTION
SHALL THE CHAIR BE SUSTAINED
PREVAILED
MAR 24, 2000
60 YEAS 53 NAYS 0 PRESENT
Y ACEVEDO Y FOWLER E LINDNER Y REITZ
N BASSI Y FRANKS Y LOPEZ N RIGHTER
N BEAUBIEN Y FRITCHEY N LYONS,EILEEN N RUTHERFORD
N BELLOCK Y GARRETT Y LYONS,JOSEPH N RYDER
N BIGGINS Y GASH N MATHIAS N SAVIANO
N BLACK E GIGLIO Y MAUTINO N SCHMITZ
Y BOLAND Y GILES N McAULIFFE Y SCHOENBERG
N BOST Y GRANBERG Y McCARTHY Y SCOTT
Y BRADLEY Y HAMOS Y McGUIRE Y SCULLY
N BRADY Y HANNIG Y McKEON Y SHARP
Y BROSNAHAN Y HARRIS N MEYER Y SILVA
Y BRUNSVOLD Y HARTKE N MITCHELL,BILL N SKINNER
Y BUGIELSKI N HASSERT N MITCHELL,JERRY Y SLONE
Y BURKE N HOEFT N MOFFITT Y SMITH
Y CAPPARELLI Y HOFFMAN N MOORE N SOMMER
N COULSON Y HOLBROOK Y MORROW N STEPHENS
N COWLISHAW Y HOWARD N MULLIGAN Y STROGER
N CROSS N HULTGREN Y MURPHY N TENHOUSE
Y CROTTY N JOHNSON,TIM N MYERS Y TURNER,ART
Y CURRIE N JOHNSON,TOM Y NOVAK N TURNER,JOHN
Y CURRY N JONES,JOHN Y O'BRIEN N WAIT
N DANIELS Y JONES,LOU N O'CONNOR N WINKEL
Y DART Y JONES,SHIRLEY N OSMOND N WINTERS
Y DAVIS,MONIQUE Y KENNER Y OSTERMAN N WIRSING
Y DAVIS,STEVE N KLINGLER N PANKAU N WOJCIK
Y DELGADO N KOSEL N PARKE Y WOOLARD
N DURKIN N KRAUSE E PERSICO Y YOUNGE
E ERWIN Y LANG N POE E ZICKUS
Y FEIGENHOLTZ N LAWFER Y PUGH Y MR. SPEAKER
Y FLOWERS N LEITCH
E - Denotes Excused Absence
[ Top ]